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The dual-specificity tyrosine phosphorylation-regulated kinase family (DYRKs) has recently 
emerged as new therapeutic targets for different kinds of cancer and neurodegenerative diseases. 
In the latest studies it was shown that DYRK1B plays a key role in cancer cell survival, and its 
inhibition induces apoptosis of cancer cells. This thesis is about the biophysical characterization of 
DYRK1B and its comparison to DYRK1A, the closest homologue. This includes establishment of 
an expression and purification protocol for large-scale protein production of DYRK1B. Buffer 
optimization by screening with thermofluor was employed to further improve the stability and 
solubility of the protein. Enzyme kinetics of DYRK1B were characterized by determination of the 
Michaelis-Menten constant. Fifty small molecular weight molecules were screened for their ability 
to inhibit DYRK1B. The results of the screening were compared with DYRK1A to determine a 
selectivity profile of these inhibitors. A point mutation of DYRK1B to mimic DYRK1A was 
introduced to further investigate the selectivity profile. Finally, the crystal structure of DYRK1A 
in complex with PKC412 was solved by molecular replacement to a resolution of 2.6 Å. The 
structure shows for the first time the formation of a disulfide bridge between the catalytic loop and 
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AIM OF STUDY 
 
 
The aim of the study is the biophysical characterization of kinases from the DYRK family. 
This family has five members and, based on the expression test which had been done prior to this 
thesis, DYRK1A and DYRK1B were chosen for more detailed characterization. Both DYRK1A 
and DYRK1B have emerged recently as novel targets for a variety of diseases. DYRK1A plays a 
critical role in neuronal development and in consequence is implicated in diseases like Alzheimer 
and Parkinson and it also plays a role in mental retardation in patients suffering from Down 
syndrome due to its gene location on the DSCR on chromosome 21. DYRK1B is associated with 
ovarian cancers, pancreatic cancers and osteosarcoma, and the inhibition of DYRK1B leads to the 
apoptosis of cancer cells. Finding selective ATP competitive inhibitors for kinase is in general a 
challenge; the close similarity between DYRK1A and DYRK1B makes it even harder to find 
selective inhibitors for these two kinases. The focus in this thesis is on DYRK1B which has the 
highest sequence similarity in the kinase domain to DYRK1A among all DYRKs, but no structural 
details have been published. The aim of the first part is to develop an expression and purification 
protocol for DYRK1B that allows the characterization of this protein in terms of stability, 
phosphorylation pattern and kinase activity. The second part includes the screening for small 
molecular weight inhibitors and a comparison of the inhibitory activity of these inhibitors with 
DYRK1A. The third part of the thesis is the cloning of DYRK1B mutants to study the inhibitor 
selectivity profile and the residues involve in the enzyme kinetics. The last part is the 



















1.1 Protein kinases 
 
The kinases are a large group of phosphotransferases, i.e., enzymes which catalyze the 
transfer of the γ-phosphate group from an adenosine-5‟-triphosphate (donor) to a hydroxyl-group 
(acceptor) of the specific substrates
1




 are required for ATP 
binding and assistance of the phosphorylation reaction. Once phosphorylated, the kinase substrate 
may be functionally altered, and subsequently initiate the transmission of a biological signal to its 
own set of downstream targets.   
Human kinases are involved in almost every cellular process, and are essential for signal 
transduction cascades in the cell. For example, protein kinase A (PKA, or cyclic AMP-dependent 
kinase), belonging to the AGC kinase group, controls the expression of large number of genes via 
the phosphorylation of transcription factor CREB
2
, and, as a multiple substrate kinase, it is 
involved in the regulation of proliferation and differentiation of cells
3
.  
Human kinases have been extensively studied in the past, and are still an intensely 
investigated research field. Manning et al. in 2002 have classified the more than 500 human 
kinases, termed „the human kinome‟, into seven groups based on the sequence similarity in the 
kinase domain
4
. Based on their ability to phosphorylate serine/threonine or tyrosine residues the 
protein kinases are divided into the two subdivisions: serine/threonine kinases (phosphorylate 
alcohol groups on serine or threonine) and tyrosine kinases (transfer the phosphate to the phenol 
group of tyrosine)
5
. However, there is a group of protein kinases, termed as „dual-specificity‟ 
kinases, able to phosphorylate both serine/threonine and tyrosine residues on their targets
6
. 
 From this perspective it is evident that abnormal function of kinases can lead to numerous 
diseases. For instance, mutation of the genes encoding growth factor receptors (e.g. EGF-R, 
epidermal growth factor receptor; VEGF-R, vascular endothelial growth factor receptor), which 
contain a tyrosine kinase domain responsible for transduction of the signal from the growth factors 
to cytoplasm in the cell, causes the alteration of structure of kinase domain leading to a ligand-
independent activation of the growth factor receptor and dysregulation cell growth
7
. This type of 
dysregulation is often involved in tumor pathogenesis
8
.  
Protein kinases represent an interest for the pharmaceutical industry because they are 
considered as therapeutic targets for diseases including diabetes
9
, neurodegenerative diseases as 
Alzheimer disease
10










1.2 Structure of kinase domain 
 
Kinases do not usually consist of the kinase domain alone, but have additional regulatory 
domains in the sequence required for their function, localization, and inter-protein interactions. 
Some kinases like CDKs need a second partner, cyclins, to be fully active
14
. Nevertheless, human 
kinases share a similar fold, the kinase domain, comprising an N-terminal lobe (N-lobe) with five 
antiparallel β-strands and a conserved regulatory αC-helix, and a larger C-terminal (C-lobe) 
consisting of α-helices
15
. The N-lobe and C-lobe are connected by a hinge region which is an 




Figure 1. Stereo image of the kinase domain with several of its key features. The major structural elements are labeled. The 
structure of DYRK1A (3ANQ16) was used to illustrate the overview of kinase domain. 
 
 
For most kinases, the αC-helix is located between β3 and β4. Kinases have in the activation 
loop one or more residues that can be phosphorylated. The activation loop is located at the C-lobe 
and starts from DFG-motif and ends with a conserved W/F/YRAPE motif (RFYRSPE in 
DYRKs)
17
. Depending on the kinase group and family, the phosphorylation is on a serine, 
threonine or tyrosine residue. This leads to an activation of kinase. In DYRK1A/B the 
phosphorylation occurs on the second tyrosine in the YQY motif during autoactivation 
immediately after translation by an intramolecular reaction
18-20




the conserved YQY motif in DYRKs makes a contact with two arginines located at the end of the 
activation loop (R
325
FYR in DYRK1A and R
276
FYR in DYRK1B). In the DFG-motif the aspartate 
is the most conserved residue because it forms a contact with the phosphate groups of ATP either 
directly, or through magnesium. The phenylalanine in DFG is responsible for the hydrophobic 
interaction with the αC-helix and the correct orientation of aspartate in the DFG-motif
21
. In the 
literature, the active conformation of kinases is often referred to “DFG-in” conformation, while 
“DFG-out” corresponds to inactive state of protein kinases.   
The catalytic loop is involved in transfer of the γ-phosphate to the substrate. A typical, highly 
conserved, motif of the catalytic loop in the kinome is HRD; however in the DYRK family a HCD 
motif is highly conserved in the catalytic loop instead. Another important part of the kinase 





KGSFG in DYRK1B). It is located between β1 and β2 and constitutes a part of 
ATP-pocket from the N-lobe. An important residue in the ATP-pocket is the “gatekeeper” which 
is responsible for the selectivity of inhibitors. DYRKs have a phenylalanine as a gatekeeper (F238 
in DYRK1A and F190 in DYRK1B) which is located at the beginning of the hinge region. 
 
1.2.1 Architecture of the ATP-pocket  
 
Crystal structures of protein kinases have revealed that ATP binds at a specific region, called 
the ATP-pocket or cleft, between the N- and C-lobes of the kinase domain, connected by a hinge 
region. Protein kinases evolved to bind ATP, and therefore many residues forming the ATP-
pocket are highly conserved among group and families of protein kinases. This makes it a 
challenge for the scientist to develop a selective inhibitor for a specific kinase, because the 
majority of the protein kinase inhibitors are ATP-competitive, i.e. the inhibitors have to mimic 
ATP and bind to the ATP-pocket. A. Vulpetti  and R. Bosotti have studied the key structural 
features of ATP-pocket, involved in the binding of ATP and inhibitors by multiple sequence 
alignment of 478 protein kinases, comprising the human kinome
22
. They established that in the 
ATP-pocket, five regions responsible for the binding of different chemical group on the ATP 
molecule can be distinguished. First, the adenine region: the adenine ring forms two hydrogen 
bonds with the backbone of the hinge region and adenine core interacts with the hydrophobic 
residues via non-polar interactions. Second, the sugar ring: the ribose forms one hydrogen bond 
with a lysine, histidine or other polar residues of the C-lobe of kinase domain. Third, the 
phosphate region: the triphosphate group forms one hydrogen bond with a highly conserved 
16 
 
lysine. Fourth and fifth, the buried region and solvent accessible region are not occupied by ATP, 
but comprise a set of residues which are the source of sequence divergence among the kinases. 
 
1.3 DYRK family 
 
The Dual-specificity tYrosine phosphorylation-Regulated Kinases (DYRKs) are called “dual-
specificity”  kinases because of their ability to become active by autophosphorylation of a tyrosine 
residue in the activation segment during translation, and after that, the members of DYRK family 
are capable of phosphorylate serine or threonine residues of exogenous substrates, losing a feature 
of a tyrosine kinase
18
. However, latest research showed that the tyrosine phosphorylation is not 
restricted to the autoactivation during translation but that the mature DYRK1A kinase remains 
some tyrosine phosphorylation activity
23
.   
 DYRKs are an evolutionary conserved family whose members are found in different 
branches of life. DYRKs are found in yeast, for example, Yak1p from Schizosaccharomyces 
pombe which was primarily characterized by Garret S. et al.
24
. In nematodes: particularly 
Caenorhabditis elegans, where there are two genes, mbk-1 and mbk-2 encoding the kinases, 
MBK-1 and MBK-2 (homologs of minibrain kinases), which were identified as members of 
DYRK family
25
. However, the characterization by Tejedor F. et al. of the mnb (minibrain) gene 
encoding for MNB (minibrain kinase) kinase found in Drosophila melanogaster attracted the 
attention of the scientific world to these kinases as their dysfunction leads to the reduction of the 
brain size in the optic lobes of adult flies, notably indicating the role of MNB neurogenesis
26
.  
 Human homologs of DYRKs belong to the CMGC group (according to the Manning G. et al. 
classification
4
) which also includes the cyclin-depended kinases (CDKs), mitogen-activated 
protein kinases (MAPKs), glycogen-synthase kinase-3 (GSK3) and CDK-like kinases. The human 
DYRK family includes five members: DYRK1A, DYRK1B, DYRK2, DYRK3 and DYRK4. 
DYRK kinases are further categorized as class I (DYRK1A and DYRK1B) and class II (DYRK2, 
DYRK3 and DYRK4)
27
. The comparison of the protein structure of human DYRKs is depicted in 
Figure 2. DYRK1A and DYRK1B have a DYRK homology (DH)-box typical for class I of 
DYRKs at the N-terminus, while the members of class II differ by the presence of an N-terminal 
autophosphorylation accessory region (NAPA) at the N-termini. Class I of DYRKs have a region 
rich in proline, glutamic acids, serine and threonine, called PEST (sequence common to rapidly 




region enriched in serine and threonine residues (S/T). Members of the DYRK family are capable 




Figure 2. Protein structure scheme of the DYRKs. Kinase domain (green), N-terminus (blue) at the left of kinase domain, C-
terminus (blue) at the right of kinase domain; NLS, nuclear localization signal; DH, DYRK-homology box; NAPA, N-terminal 
autophosphorylation accessory region; Kinase domain; PEST, motif rich in proline, glutamic acid, serine, and threonine residues; 
His, polyhistidine stretch; and S/T, region enriched in serine and threonine residues. Black lines indicate protein regions affected by 





Leder S. et al. has performed the cloning of DYRK1B by cDNA and has analyzed its tissue 
distribution in human
30
. The mirk gene (in some literature the DYRK1B kinase is also called 
MIRK, or minibrain-related kinase, and, thus, gene mirk encodes for MIRK or DYRK1B; 
however, in this thesis the DYRK1B name is used to avoid confusion) is located in the 19q13.1 
chromosome. S. Leder shows that DYRK1B has three splicing variants (629, 601, and 589 AA) 
and expresses at low levels in human tissues, except for the skeletal muscles where it is abundant. 
Later, a myogenesis (i.e. formation of muscular tissue) was exploited as a model system to 
investigate the functions of DYRK1B in myoblast differentiation by Lu J. et al.
31
, Deng X. et al.
32
 
and Mercer S. et al.
33
. It was shown that the level of DYRK1B protein is low in dividing 
myoblasts; however, when the myoblasts enter into a differentiation stage the expression of 
DYRK1B increases at least 10-fold and remains elevated in mature cells. Deng X. et al. have 
shown that induction of the mirk gene in myoblasts is induced by Rho proteins (family of 
GTPases) and inhibitors of MEK (mitogen-activated protein kinase)
32
. Moreover, DYRK1B 
controls the cell cycle by an arrest of cycling myoblasts in a G0/G1 state through the 





However, in spite of the low expression of mirk gene in normal tissues (except skeletal 
muscles), Lee K. et al. studies have found an elevated expression level of mirk in colon carcinoma 
cells, lung carcinoma cells, ovarian carcinoma cells, chronic myelogenous leukemia cells, 
lymphoblastic leukemia cells and melanoma cells
34
.  
Mercer S. studies have demonstrated that DYRK1B is also overexpressed in 
rhabdomyosarcoma cells (i.e. skeletal muscle-derived tumor), where the depletion of DYRK1B 
gene performed by small interference RNAs (siRNAs) leads to an induction of apoptosis of the 




Yang C. et al. have investigated the role of DYRK1B in osteosarcoma
36
. They have shown 
that the knockdown of the DYRK1B gene by siRNAs facilitates to the termination of the cancer 
cell growth and an increased number of cells entering to apoptosis. Yang C. et al. have also shown 
that that expression of DYRK1B is correlated with poor prognoses for patients and low survival, 
and noted that DYRK1B may serve as a biomarker for a prognosis
36
.  
Likewise, Gao J. et al. have studied the role of DYRK1B in non-small cell lung cancer cells 
(NSCLC) and found that DYRK1B is expressed at high levels in the majority of NSCLC. They 
have employed the similar siRNA knockdown of DYRK1B expression, and results have shown 
that NSCLC exhibited an inhibition of cell growth and induction of an apoptosis compared to non-
depleted DYRK1B cells. Moreover, knockdown of DYRK1B enhanced the sensitivity of NSCLC 
to cisplatin-induced apoptosis
37
. Increased sensitivity of cancer cells to cisplatin was also 
demonstrated by Hu J. and Friedman E. in the study of ovarian cancer cells where DYRK1B 
depletion leads to increasing of ROS (reactive oxygen species) assisting to further elevation of 
ROS by cisplatin that, finally, kills the cancer cell
38
.  





.  This author has done a tremendous amount of work summarizing the role 
of mechanism of DYRK1B in tumor progression. The author explained that Mirk/DYRK1B, 
which is not mutated in cancer cells, sustains the quiescent state of the cancer cells through the 
phosphorylation-dependent destabilization of cyclin D1 at T288
41
, and stabilization of the CDK 
(cyclin-dependent kinase) inhibitor p27 at S10
42
. DYRK1B in the cancer cells is activated by the 
oncogenic K-ras signaling
43
. This mechanism enables halting of the cell cycle at G0 stage 
(quiescence or resting stage), however, the inhibition of DYRK1B, as was shown in the study of 
Hu J. et al. 
44
, was able to induce the apoptosis of cancer cells (Figure 3).  
Taken together, DYRK1B is a new emerging target for cancer therapy for osteocarcoma, lung 




investigation of binding features of this kinase with molecular weight inhibitors has become an 
urgent task.  
 
Figure 3. DYRK1B inhibition leads to the cell death. S (synthesis stage), M (mitosis), G1 (Gap 1), G2 (Gap 2), G0 (Gap0 or 





The DYRK1A gene is located in the Down syndrome critical region (DSCR) on chromosome 
21
45
 and the overexpression of DYRK1A in patient suffering from Down syndrome (DS) is 
coupled to mental retardation
46
. Patients with Down syndrome develop an Alzheimer-like 
dementia
47
 relatively early compared to the general population.  Besides its involvement in DS, 





 and Huntington‟s disease
49
. Regarding to the Alzheimer 
disease, as reviewed by Smith B. et al, DYRK1A directly phosphorylates tau protein promoting a 
following multiple site phosphorylation of tau by GSK 3β kinase and aggregation of the 






1.3.3 Sequence alignment of DYRK1A and DYRK1B 
 
The closest homolog to DYRK1B is DYRK1A. The identity over the whole enzyme is 73.9% 
(89.4% similarity) and in the kinase domain it is 85.0% (95.6% similarity). The pairwise sequence 
alignment was performed by the on-line software LALIGN
51
. Within the ATP pocket there is only 
one residue M240 in DYRK1A, L192 in DYRK1B at the hinge region, which is different between 




Figure 4. Pairwise sequence alignment of the DYRK1A (125-490 AA) and DYRK1B (78-451 AA). The sequences were 
obtained from UniProt database (accession numbers: Q13627 for DYRK1A and Q9Y463 for DYRK1B)52. The DYRK1A sequence 
comprising the kinase domain residues 125-493 was aligned with the kinase domain of DYRK1B including the residues 78-451 of 
the designed construct. The secondary structure annotation corresponds to the crystal structure of DYRK1A (2WO653). Residues 
depicted in white and highlighted by red boxes are identical between the two sequences. Residues shown in red and highlighted by 
blue boxes are similar. The secondary structure elements are shown above the aligned sequences. Alpha helices are represented by 
spirals and beta strands by arrows.  The clustalW2 online software was used to compute the pairwise sequence alignment54.  The 
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1.4 Kinase inhibitors 
 
Since kinases are an important in processes such as cell cycle control and signaling pathways, 
they are an attractive target for drug development and inhibitor design
56
. Small molecular weight 
inhibitors (molecular weight range 200-600 Da) are able to effectively inhibit the kinases and 
prevent the development of diseases. One of the best examples among the kinase inhibitors is the 
Imatinib/Gleevec (Novartis, Switzerland) used in the therapy of patients with chronic 
myelogenous leukemia (CML) caused by formation of the so-called Philadelphia chromosome
57
 
(i.e. chromosomal defect leading to formation of BCR-Abl oncogene). Gleevec became a 
revolutionary drug, first, because it was a rationally designed inhibitor and, second, it is able to 
selectively inhibit the BCR-Abl kinase and effectively treat CML
58,59
.  
Inhibitors of protein kinases can be categorized into several types based on the interaction 
between kinase and inhibitor
60
: 
1. Type I kinase inhibitors. ATP-competitive, inhibitors can bind through hydrogen bonds 
with the residues of the hinge region. Inhibitors bind to the ATP-pocket at the active 
conformation of the kinase, i.e DFG-in form. 
2. Type II kinase inhibitors, non-ATP-competitive inhibitors, are able to bind to the ATP-
pocket through residues of hinge region and hydrophobic interactions. Inhibitors bind to a 
DFG-out form targeting the inactive kinase. 
3. Type III inhibitors, allosteric inhibitors, are able to bind to a binding site outside of ATP-
pocket.  
4. Type IV inhibitors, are able covalently bind to the active site of kinase domain, usually, 
through a cysteine residue. 
 
Inhibitors can also be classified based on the source of origin, for example natural or 
synthetic. 
Close attention has been given to the problem of development of a highly selective inhibition 
for kinases whose malfunction is a key factor in a pathogenesis of diseases. In order to distinguish 
a key structural feature responsible for the selectivity, a comprehensive analysis of kinase 
inhibition is required
61
. E. Åberg et al. studied the key residues which determine the inhibitor 
selectivity for the AGC kinase group (include PKA, PKC etc)
62
. E. Åberg et al. described that for 
the ATP-pocket binding, the important residue is the gatekeeper, the presence of a cysteine residue 
at or near the ATP-pocket (may serve as a target for formation of covalent bond with inhibitors) 
22 
 
and the second residue in the glycine-rich loop which is usually an aromatic residue and may 
influence on the hydrophobic interaction with inhibitor. The inhibitors for the kinase of interest 
may be designed with respect to the residues listed above.   
Ambit Bioscience Company (USA) have performed a profile for 72 known kinase inhibitors 
(at concentration of 10 µM) against 442 kinases to determine the dissociation constant Kd and 
provided an overview over the kinase selectivity
63
. The profiling demonstrated that the known 
inhibitors can bind to distinct related kinases. This makes it possible to change an application for 
particular inhibitors. Statistic handling in this research showed that among the selective inhibitors 
the fraction of type II inhibitors is higher compared to the fraction of type I inhibitors. However, it 
is not a fixed rule: some type I inhibitor shown higher selectivity across the kinome and some 
type II inhibitor demonstrated weak selectivity.  
In summary, the selectivity of kinases is a complicated field and vast numbers of factors are 
involved in rational inhibitor design. Development and design of selective inhibitors remains an 
urgent field in scientific and pharmaceutical research. 
 
1.4.1 DYRK inhibitors  
 
The DYRK1B inhibitor RO5454948 (Figure 5, a) has been shown to induce apoptosis of 
quiescent pancreatic cancer cells which are normally resistant to the conventional cancer 
chemotherapeutics
64
.  RO5454948 was identified by Roche generic kinase inhibitor library. Ewton 
D.Z. et al. have demonstrated that in Panc1 (a pancreatic cancer cell line) with an amplified 
DYRK1B, the treatment of the cell by RO545494 leads to a decreasing of the fraction of the 
cancer cells in the G0 stage by around 60%. This was examined by flow cytometry method
65
. Hu 
J. et al. have studied the inhibition of RO5454948 in ovarian cancer cells and demonstrated that 
Mirk/DYRK1B inhibition leads to an increasing of cyclin D levels and consequently induces the 
cell cycle
44




                                                                     
 
Figure 5.Chemical structure of some DYRKs inhibitors. a) RO5454948 is a known DYRK1B inhibitor64; b) D15 is a DYRK1A 
inhibitor; c) harmine is a DYRK1A/1B inhibitor16, d) INDY is DYRK1A inhibitor16. The structures of inhibitors were drawn in 
Maestro suit (Schrodinger)66. 
 
 Crystal structures in complex with inhibitors (Figure 5, b-d) have been solved for DYRK1A. 
The crystal structure of DYRK1A in complex with inhibitor INDY (3NAQ, Figure 5, d) has been 
published by Ogawa Y. et al.
16
. INDY is a type I inhibitor which binds with a Ki of 180 nM. This 
inhibitor binds to the hinge region and forms two hydrogen bonds. The first one is between the 
hydroxyl oxygen and backbone amide of Leu241 of the hinge and the second one is between the 
carbonyl oxygen and Lys188. Another structure by Ogawa Y. et al. is DYRK1A in complex with 
harmine (3NAR, Figure 5, c). Harmine binds to ATP-pocket (adenine region) via two hydrogen 
bonds: first one between the pyridine nitrogen and Lys188; second one between the methoxy 
group and backbone amide nitrogen of Leu241. Harmine has an IC50 of 350 nM. D15 inhibitor 
(2WO6, Figure 5, b) interacts with the hinge through a series of three hydrogen bonds between 
the backbone of Glu239, Met240 and Leu241. D15 also forms a salt bridge between a primary 
amide of inhibitor and carboxylate of Asp307
53
















PKC412 (midostaurin, N-benzoyl-staurosporine), is an analog of the pan-kinase inhibitor 
staurosporine, an alkaloid isolated from Streptomyces staurosoreus
67
. PKC412 has a more 
selective inhibition profile compared to staurosporine and its main targets are the isoforms of 






. PKC412 is currently under investigation as a 
treatment of acute myeloid leukemia
71,72
. The selectivity profile of PKC412 compared to the 






Figure 6. Kinome interaction map. a) PKC412, b) Staurosporine. The kinase maps were kindly provided by R.A. Engh, adapted 









1.5 Enzyme Kinetics 
 
Enzymes are able to dramatically increase the rate of chemical reactions in the cell
73
. First 
order enzyme kinetics may be described by simple conversion of substrate S to the product P 





where enzyme E form a complex with the substrate S at the rate k1, while the reverse reaction, 
the dissociation of the complex ES  (  →    )  ccurs at the rate k-1. The second k2 rate 
(denoted also as kcat) describes the dissociation rate of ES complex and the product formation 
from the ES complex. The reverse reaction, forming the ES complex out of the product is assumed 
to be infinitesimally small for many enzymes
74
.  
The activity of enzymes is dependent on several factors like pH, salt, substrate and product 
concentration and temperature. Enzymes have in general a temperature and pH optimum where 
the activity is highest
75
.  The enzyme activity can also be influenced by the presence of inhibitors.  
Inhibitors decrease the activity of enzymes and, as used in this thesis, kinase inhibitors are able to 
decrease an efficiency of the kinase catalytic activity and thus, lead to a decreasing or even partial 
blockage the downstream mediation of cellular processes
76
.  
In this master thesis, a set of inhibitors was tested by the Cook assay
77
, a kinase activity assay 
that measures the NADH consumption while keeping the ATP concentration constant. In order to 
compare the inhibition efficiency for the tested inhibitors we need to determine the absolute 




   




       
 
where IC50 is the concentration of inhibitor causing 50% reduction of catalytic activity of the 
kinase, [ ] is the substrate concentration, i.e. ATP concentration, Km is a Michaelis-Menten 
constant that can approximate the affinity of substrate (ATP) to the enzyme. The Km value is equal 
to the substrate concentration at which the enzyme activity is half of the maximum activity.  





E + P 
26 
 
Leonor Michaelis and Maud Menten were the scientists who established the fundamental enzyme 
kinetics in 1913
79
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where the Vo is initial velocity of the catalytic reaction, Vmax is a maximum velocity, [ ] is the 
substrate concentration and Km is a Michaelis-Menten constant. The equation (2) is a 
mathematical representation of Michaelis-Menten curve depicted on the Figure 7: 
 
                       
Figure 7. The Michaelis-Menten curve. The Michaelis-Menten kinetics shows that initial velocity at high substrate concentration 
cannot further increase and reaches a maximum velocity: Vmax.  Km is the Michaelis-Menten constant, Vmax is the maximum 
velocity, Vmax/2 is a half of the maximum velocity, [ ] is the substrate concentration. 
 
The Michaelis-Menten equation requires a steady-stay condition, i.e. the period when the 
concentration of ES complex remains constant with time
81
.  
Originally the Michaelis-Menten equation was used to describe kinetics of first order 
reactions, meaning that only one substrate is used in the reaction.  However, kinases are catalysts 
of a reaction involving two substrates
82
. As described by Alistair Rogers and Yves Gibon, there 
are three major classes of mechanisms of catalytic reaction with two substrates: random substrate 
binding, ordered substrate binding and the Ping-Pong mechanism
74
. For most kinases it is 
unknown which mechanism they follow but for some kinases a mechanism was described. For 
example, Szafranska, A.E. et al. have described the kinetic mechanism of p38 MAP kinase α, a 
kinase belonging to the same CMGC group as the DYRK family. The author found out that p38 
MAP kinase α exploits a partial rapid-equilibrium random order ternary-complex mechanism
83
.    
Despite on the complexity bisubstrate catalytic reaction the Michaelis–Menten equation 
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2 MATERIALS AND METHODS 
 
2.1 Buffers and solutions 
 
The buffers and solutions used in this thesis are listed in the Table 1. Buffer C and Buffer G 
were filtered by 0.45 µl membrane filter prior to gel filtration.  
 
Table 1. Buffers and solutions used for cloning, expression and purification of DYRK1B and its mutants. 
Solution/buffer Contents 
Amp 100 mg/ml Ampicillin in MilliQ water 
Cam 34 mg/ml Chloramphenicol in 100% ethanol 
Kan 50 mg/ml Kanamycin in MilliQ water 
IPTG 1 M IPTG 
LB-agar 
1% (w/v) Bacto Tryptone, 0.5% (w/v) Yeast extract, 1% (w/v) NaCl, 1.5% (w/v) 
Agar-agar in MilliQ water 
LB media 
1% (w/v) Bacto Tryptone, 0.5% (w/v) Yeast extract, 1% (w/v)  NaCl in MilliQ 
water 
SOC media 
2% (w/v) Bacto Tryptone, 0.5% Yeast extract, 10 mM NaCl, 1 mM MgCl2, 2.5 
mM KCl, 10 mM MgSO4, 0.4 % (w/v) Glucose in MilliQ water 
TB media 
1.2% (w/v) Peptone, 2.4% (w/v) Yeast extract, 72 mM K2HPO4, 17 mM 
KH2PO4, 0.4% (v/v) Glycerol 
2YT media 1.6% (w/v)  Peptone, 1%  (w/v) Yeast extract, 86 mM NaCl in MilliQ water 
TAE buffer 40 mM Tris, 20 mM Acetic acid, 1 mM EDTA in MilliQ water 
TRIS-Glycine 
buffer 
0.25 M  Trizma Base, 1.95 M Glycine, 1% (w/v) SDS in MilliQ water  
Buffer A 50 mM Na2HPO4 pH 8.0, 500 mM NaCl in MilliQ water 
Buffer B 50 mM Na2HPO4 pH 8.0, 300 mM NaCl, 500 mM Imidazole in MilliQ water 
Buffer C 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 2 mM β-ME in MilliQ water 
Buffer D 50 mM MOPS pH 6.8, 50 mM KCl, 2 mM β-ME in MilliQ H2O 
Buffer E 50 mM HEPES pH 8.0, 50 mM KCl, 250 mM NaCl in MilliQH2O 
Buffer F 
50 mM HEPES pH 8.0, 50 mM KCl, 250 mM NaCl, 500 mM Imidazole in 
MilliQH2O 








2.2 Cloning of DYRK1B wt 
 
The sequence of NM_004714 cDNA clone of DYRK1B (OriGene
84
) was used to design the 
DNA construct suitable for protein expression. The full length protein comprises 629 amino 
acids
27,30
. The length and the boundaries of the construct are based on the published crystal 
structure of the DYRK1A (3NAR
16
) protein including kinase domain and showing the highest 
level of sequence identity (85%) with DYRK1B. The full length amino acid sequence of 
DYRK1B and the chosen protein construct (residues 78-451, where 111-431 is the kinase domain) 
for cloning are shown in Figure 8. 
  
        10         20         30         40         50         60  
MAVPPGHGPF SGFPGPQEHT QVLPDVRLLP RRLPLAFRDA TSAPLRKLSV DLIKTYKHIN  
 
                     70       78           90        100        110        120  
EVYYAKKKRR AQQAPPQDSS NKKEKKVLNH GYDDDNHDYI VRSGERWLER YEIDSLIGKG  
 
       130        140        150        160        170        180  
SFGQVVKAYD HQTQELVAIK IIKNKKAFLN QAQIELRLLE LMNQHDTEMK YYIVHLKRHF  
 
       190        200        210        220        230        240  
MFRNHLCLVF ELLSYNLYDL LRNTHFRGVS LNLTRKLAQQ LCTALLFLAT PELSIIHCDL  
 
       250        260        270        280        290        300  
KPENILLCNP KRSAIKIVDF GSSCQLGQRI YQYIQSRFYR SPEVLLGTPY DLAIDMWSLG  
 
       310        320        330        340        350        360  
CILVEMHTGE PLFSGSNEVD QMNRIVEVLG IPPAAMLDQA PKARKYFERL PGGGWTLRRT  
 
       370        380        390        400        410        420  
KELRKDYQGP GTRRLQEVLG VQTGGPGGRR AGEPGHSPAD YLRFQDLVLR MLEYEPAARI  
 
       430        440          451      460        470        480  
SPLGALQHGF FRRTADEATN TGPAGSSAST SPAPLDTCPS SSTASSISSS GGSSGSSSDN  
 
       490        500        510        520        530        540  
RTYRYSNRYC GGPGPPITDC EMNSPQVPPS QPLRPWAGGD VPHKTHQAPA SASSLPGTGA  
 
       550        560        570        580        590        600  
QLPPQPRYLG RPPSPTSPPP PELMDVSLVG GPADCSPPHP APAPQHPAAS ALRTRMTGGR  
 
       610        620  






Figure 8. Amino acid sequence of DYRK1B. DYRK1B amino acid sequence was downloaded from Uniprot database:  code 
Q9Y46385. The UniProt database format is used to illustrate the amino acid sequence of DYRK1B. The kinase domain composed 
of amino acids from 111 to 431 (bold sequence). The amino acid sequence 78-451 (green) was chosen for cloning. The construct 








Gateway cloning strategy together with TOPO
®
 cloning was employed to create the 
expression clone of DYRK1B. The following steps are included in the TOPO
®




1. Amplification of blunt-end PCR product (selection of DNA template, primer design, PCR 
catalyzed by Phusion polymerase, agarose gel electrophoresis and extraction of blunt-end 
PCR product) 
2. Construction of  a Gateway entry clone by TOPO® cloning (reaction set-up, transformation 
in competent cells, analysis of colonies, plasmid isolation and purification, sequencing of 
selected clones) 
3. Gateway cloning (LR recombination reaction, transformation, analysis of colonies, 
amplification and purification). 
 
 
2.2.1 Cloning of PCR product encoding the DYRK1B kinase domain 
 
In the first step of creating the expression construct of the DYRK1B kinase domain a PCR 
product suitable for TOPO
®
 cloning was created. The TOPO
®
 cloning reaction creates a construct 
that acts as the entry clone for the following Gateway cloning reaction. The pENTR Directional 
TOPO
®
 cloning kit was purchased from Invitrogen (Life Technologies).  A detailed description of 
the TOPO
®





 cloning method exploits a topoisomerase which was originally discovered in the 
Vaccinia virus
89
. This enzyme has a high affinity for duplex DNA and it binds to the specific site 
CCCTT. After binding to DNA at the specific site the topoisomerase cleaves the phosphodiester 
backbone in one strand of the double-stranded DNA and covalently binds to this strand with a 
tyrosine residue via 3' phosphate. The second remaining strand, also called an overhang, has the 
sequence GTGG (specific for the pENTR Directional TOPO
®
 cloning kit), which can anneal to the 
sequence CACC at the 5' end of PCR product. Therefore, one of the parameters in the primer 
design is that the forward primer must begin from the sequence CACC to ensure perfect annealing 
to the TOPO
®
 vector and in addition to ensure the correct orientation of the PCR product within 
the TOPO
®
 vector. The forward primer also contains a sequence encoding a TEV recognition site 
for tag-cleavage and 6 triplets coding for amino acids 78-83 at the N-terminal end of DYRK1B. 
According to the user manual of TOPO
®
 cloning kit the reverse primer does not contain any 
sequence which is complementary to the overhang sequence GTGG
88
. This is a necessary 
requirement for a correct orientation of PCR product of interest. The reverse primer is 
30 
 
complementary to the nucleotide sequence encoding the last 8 amino acid residue at the C-
terminal end of designed construct and includes the stop codon TGA (Figure 9). The primers were 
designed by Dr. Espen Åberg in Vector NTI
®
 Express Designer Software
90
.    
                
a) FW 5’CACCGAAAACCTGTATTTTCAGGGAGCTTCAGATTCGAGCAACAAGAAG 3’ 
b) RV 5’TCACGAGGTGGAGGCACTGCTGC 3’ 
Figure 9. Primers for DYRK1B construct. a) Forward primer for the DYRK1B construct. Nucleotide sequence in bold is 
required for the annealing with the overhang of the TOPO® vector, underlined sequence encodes for the TEV recognition site, 
sequence in italic is complementary to the first amino acid residues. b) Reverse primer for the DYRK1B construct.  The reverse 
primer is complementary to the last 8 amino acid residues of the DYRK1B construct (italic). Stop codon is shown in bold.  
 
The primers for the DYRK1B construct were purchased from SigmaAldrich, and as a 
template the pDONR223-DYRK1B (Addgene plasmid 23761
91
 containing full length DYRK1B 
clone) was used for the PCR. The Addgene plasmid 23761 was amplified in DH5α E. coli 
(transformation was performed according to the protocol
92
) and purified by QIAprep spin 
Miniprep kit
93
 (QIAGEN). The concentration of the amplified DNA plasmid was measured by 
Nanodrop.  
The primers were dissolved in MilliQ water to a concentration of 100 pmol/µl.  The reaction 
mixture, composed of 200 pg of DNA template, 0.5 µM of forward and reverse primers, 200 µM 
of dNTPs and 1xHF buffer, was assembled on ice. The reaction was filled up with nuclease-free 
water to 20 µl. 0.04 U/µl of Phusion Polymerase (BioLabs) was added to the reaction mixture at 
the last step prior to the thermal cycling according to the protocol of the Phusion Polymerase
94
 .  
Dyad DNA Engine (BIO-RAD) thermal cycler was employed to run the following steps 
summarized in Table 2. Gradient setting was used to cover a broader range of annealing 
temperatures.  
 
Table 2. Thermocycling conditions for cloning by the Phusion Polymerase. Four temperatures 50  C, 55.5  C, 66  C, 70  C were 
chosen in the settings of the thermocycler program. 
Cycle Temp,  C Time Step 
1 98 30'' initial denaturation 
30 
98 10'' denaturation 
50-70 30'' annealing 
72 45'' extension 
1 72 10'' Final extension 






The amplified PCR product was separated by agarose gel electrophoresis to check the size 
and the integrity of the designed PCR product. Agarose was dissolved by heating in 1xTAE buffer 
to a final concentration of 0.7% (v/w).  RedSafe nucleic acid staining solution (ChemBio) was 
added to the melted agarose after it had cooled down to about 60  C. The final concentration of 
RedSafe was 0.05% (v/v). The RedSafe /agarose solution was poured into the gel cassette with a 
comb to prepare a gel with 10 wells. The comb was removed after the gel had solidified. The gel 
was placed in a chamber for electrophoresis filled with 1xTAE buffer.  The PCR product was 
mixed with 6x Gel loading Dye Blue (BioLabs) and loaded into the agarose gel. 6 µl of 1kb DNA 
ladder (BioLab) was used as a marker to analyze the size of PCR product. A PowerPac Bacis 
machine (BIO-RAD) was used for the electrophoresis at a constant voltage of 90V for 30 min.  
After electrophoresis the agarose gel was examined in Gel Doc (BIO-RAD) with UV lights. The 
band with expected size was cut from the agarose gel and the PCR product was extracted using 
QIAquick Gel Extraction kit from QIAGEN according to the kit protocol
95
. The concentration of 
extracted PCR product was measured by Nanodrop.  
 




 cloning reaction (as described above) combines the pENTR vector with the gene 
of interest.  The pENTR contains an ttL1 and an attL2 site. The presence of the attL1 and attL2 
sites makes the recombination reaction of the entry clone with a Gateway destination vector (as 
pDEST17) possible. The TOPO
®
 cloning reaction was done by mixing the purified PCR product 
and the TOPO
®
 cloning vector in a ratio 2:1 (volume ratio) together with 1µl of salt solution and 
nuclease free water provided by kit (Table 3). The TOPO
®
 cloning mixture was kept at room 
temperature for approximately 5 min.  
   
Table 3. TOPO® cloning reaction mixture 
Reagent Volume 
Fresh PCR product 1 µl 
Salt solution 1 µl 
Sterile water 3.5 µl  
TOPO
®
 vector 0.5 µl 




2 µl of TOPO
®
 cloning reaction was added to One Shot
®
 Top10 chemically competent E. coli. 
(Life Technologies). Transformation was performed according to the transformation protocol
96
 
(Life Technologies). 200µl of each transformation were spread on prewarmed LB plate containing 
50 µg/ml kanamycin. Plates were incubated overnight at 37   C. Two colonies were picked from 
the plate and cultivated in 4 ml of LB media containing 50 µg/ml kanamycin. Plasmids were 
isolated and purified by QIAprep spin Miniprep kit
93
 (QIAGEN). 
The plasmids were sequenced with the Big.Dye Terminator v3.1 sequencing kit to verify the 
correctness of the entry vector. The  two sequencing reaction per isolated plasmid (one with M13 
forward primer, another with M13 reverse) were done to check the 5‟ and 3‟ ends of construct and 
to cover the whole length of DYRK1B kinase construct. Sequencing reaction were performed 




2.2.3 Gateway cloning 
 
The Gateway cloning strategy is based on the feature of the Bacteriophage lambda which is 
able to integrate into the E. coli chromosome
98
. In order to create the expression clone, Gateway 
cloning system exploits the recombination reaction between the attL sites in entry clone and attR 
sites in the destination vectors. The scheme of recombination reaction between entry and 
destination vectors is depicted in Figure 10. 
 
 
Figure 10. The DYRK1B gene is flanked by attL1 and attL2 recombination sites in the entry vector pENTR-hsDYRK1B-
KD-451. The destination vector possesses the ccdB gene flanked by attR1 and attR2 sites. These sites are the binding sites for 
proteins comprising LR Clonase enzyme mixture which mediates the recombination reaction. Recombination occurs between 
recombination sites and as result creates the expression clone pEXP-hsDYRK1B-KD-451 and a by-product. The figure is modified 











The expression vector pEXP17-hsDYRK1B-KD-451 possesses the T7 promoter. T7 promoter 
is necessary to transcribe the gene during expression in E. coli. The expression construct has an N-
terminal 6XHis tag which allows purification of the protein of interest with immobilized metal ion 
affinity chromatography (IMAC) columns. An ampicillin resistance gene is present in the vector 
which is required for antibiotic specific selection in E. coli, thus, ampicillin has to be added to the 
media during transformation, growth and induction of bacteria.  
The recombination reaction between entry and destination vector was performed in a 1.5 ml 
Eppendorf tube at room temperature. As it is described in the user manual of the Gateway 
Technology kit
99
 (Life Technologies), the reaction mixture was composed of 200 ng pENTR-
hsDYRK1B-KD-451, 300 ng pDEST17 vector, 5x LR clonase reaction buffer and TE buffer (pH 
8.0) which was added to 16 µl.  Four µl of LR clonase enzyme mixture was added to the mixture 
and the reaction was incubated for 1 hour at room temperature. Afterwards, 2 µl of 2 µg/µl 
proteinase K was added into reaction mixture and incubated for additional 10 min at 37  C. The 
pEXP17-hsDYRK1B-KD-451 expression clone was transformed into DH5α competent E. coli. 
Transformation was performed according to the transformation protocol of DH5α competent 
E. coli provided by user manual of Gateway Technology kit (Life Technologies)
92
. 100 µl of the 
transformation mixture was spread on a prewarmed LB agar plate containing 100 µg/ml ampicillin 
and incubated overnight at 37  C. Two colonies were picked for propagation in mini cultures 
containing 4 ml of LB media with the same amount of antibiotic as described above. The mini 
cultures were incubated at 37  C overnight with 250 rpm shaking and the plasmids were isolated 




2.3 Site-directed mutagenesis DYRK1B 
 
Three point mutations L192M, Q164K and C238R were chosen to study different properties 
of DYRK1B with respect to role of these residues in activity, binding of small molecular 
inhibitors and crystallization. The L192M mutant changes the ATP binding site of DYRK1B to 
mimic the binding site in DYRK1A. The Q164K was chosen to improve crystallization ability of 
DYRK1B since this lysine residue forms intermolecular salt bridges in the crystal packing in 
DYRK1A crystal structures
16
. The C238R mutation aimed to study the influence of the HCD 
motif with a possible disulfide bridge formation and to compare it to the more conserved HRD 
motif in the catalytic loop found in the majority of the kinases in the kinome. The expression 
plasmid pEXP17-hsDYRK1B-KD-451 was used as a template for site-directed mutagenesis. The 
34 
 
primers for mutagenesis were designed with the help of the QuikChange Primer Design online 
software
100
. The designed primers were ordered from SigmaAldrich. The forward and reverse 
primers for each of the three point mutations are presented in Table 4. Codons depicted in red 
bold encode the substituted amino acid. The nucleotides underlined in red bold are the mutated 
ones.  
 
Table 4. Primers for site-directed mutagenesis. 
 
A similar strategy as described in the Quik-Change II site-directed mutagenesis protocol 
(Agilent Technologies) was used to produce the DYRK1B mutants
101
. The strategy of the site-
directed mutagenesis is depicted on the Figure 11.  
The PfuTurbo™ DNA Polymerase (Agilent Technologies) was employed for the site-directed 
mutagenesis
102
. The pEXP17-hsDYRK1B-KD-451 plasmid was used as a template. Reaction 
mixture was prepared according to the following scheme: 5 µl of 10x reaction buffer, 50 ng of 
template plasmid pEXP17-hsDYRK1B-KD-451, 1 µl 10 mM dNTPs, 1 µl 100-200 ng/µl reverse 
and forward primer. The mixture was filled up with nuclease-free water to 50 µl. 1 µl 2.5 U/µl  


































Figure 11. Strategy of the site-directed mutagenesis by QuikChange II  site-directed mutagenesis. The star    marks the site 
for the point mutation in the plasmid.   are the primers possessing the mutated codon. 1. Denaturation of the plasmid which is 
followed by annealing of specific primers. The process is executed by a temperature cycler. 2. Pfu Turbo™ DNA polymerase 
replicates the parental plasmid and incorporates the primers containing the desired mutation leading to a nicked plasmid. 3. DpnI 
digests the parental plasmid without the mutation. 4. Transformation of plasmid into competent cells where the bacteria ligate the 
nicked plasmids and amplify it. The figure is modified from QuikChange™ site-directed mutagenesis protocol (Agilent 
Technologies)101. 
 
The PCR tubes with the reaction mixture were placed in the Dyad DNA Engine (BIO-RAD) 
thermal cycler. The thermal cycling conditions for the mutagenesis reaction are listed in Table 5. 
 
Table 5. Thermal cycling condition for The PfuTurbo™ DNA Polymerase 
Cycle Temp,  C Time Step 
1 95 30'' initial denaturation 
16 95 30'' denaturation 
 
55 1' annealing 
68 1'/kb extension 
1 4 hold hold 
    
 
Afterwards, 1 µl 10 U/µl DpnI (BioLabs) was added to reaction mixture and incubated at 
37  C for 1 hour to digest parental plasmid. The plasmids containing the point mutation was 
transformed into XL10 Gold ultracompetent E. coli (Agilent Technologies). The transformation of 





250 µl of each transformation reaction was plated on LB-agar plate containing 100 µg/ml 
ampicillin. Plates were incubated at 37  C o/n. Two colonies from each plate were inoculated in 4 
ml of LB-media containing the same amount of ampicillin and incubated at 37  C o/n with shaking 
at 220 rpm. 2 ml of the mini culture were used to isolate and purify the plasmid by QIAprep spin 
Miniprep kit (QIAGEN). The concentration of the plasmid was measured by Nanodrop. Each 
plasmid was analyzed by sequencing. Sequencing reaction was composed according the protocol 




2.4 Expression of DYRK1B wt and mutants 
 
2.4.1 Transformation into expression strain 
 
BL21-CodonPlus(DE3)-RIL E. coli strain
104
 (Agilent Technologies) was used for the 
expression of DYRK1B wt, DYRK1B Q164K, DYRK1B L192M and DYRK1B C238R. 1 µl of 
the plasmid was transferred into 50 µl of competent cells and incubated for 20 min on ice. BL21 
E. coli competent cells were heat-shocked in water bath at 42  C for 45 sec followed by incubation 
on ice for 5 min. 500 µl of LB media containing 100 mM of glucose was added to the BL21 cells 
and the cells were incubated at 37   C for 1 hour with shaking at 220 rpm. In order to produce the 
starter culture for expression  250 µl LB media with BL21 cells were resuspended  in 50 ml 2YT 
media containing 100 µg/ml of ampicillin and 34 µg/ml of chloramphenicol for selection. The 
starter culture was incubated in sterile flasks at 37  C o/n with shaking at 220 rpm. 
 
2.4.2 Expression of DYRK1B wt and mutants 
 
For expression of the DYRK1B wt and the mutants a starter culture was prepared as described 
above. For large scale expression 2-4 L of TB (or 2YT) media were used for each of the 
constructs. 25 ml of starter culture was inoculated into 1 L of TB (or 2YT) media containing 100 
µg/ml of ampicillin and 34 µg/ml of chloramphenicol. The 2.5 L sterile baffled Erlenmeyer flasks 
with the expression media were incubated at 37  C to grow the bacteria. The optical density of the 
cultures was measured at a wavelength of 600 nm in a spectrometer to observe the growth rate of 
the bacteria. The cultures were incubated at 37  C until the OD600nm reached 1.6-1.8. (Cultures 
grown in 2YT media were induce at an OD600nm of ~0.7) The cultures were than induced by 1 mM 




2.5 Cell disruption 
 
The cell pellets from the 2-4 L TB media were resuspended in approximately 50-70 ml lysis 
buffer and transferred into a 100 ml glass beaker. The beaker with the resuspended cells was 
immediately placed in an ice/water mixture where it was kept during cell disruption. Cell 
disruption was performed by sonication with following settings: 5 sec pulse on, 4 sec pulse off, 
50% of amplitude and maximal temperature cut of 8  C to avoid overheating of the sample. The 
cells were sonicated by the Vibra-Cell sonicator (Sonics) for 15 min (total time 27 min). After 
sonication, the disrupted cells were transferred in centrifuge tubes, and spun down at 20000 rpm 
for 45 min at 4  C. The supernatant was collected and pellets discarded. The supernatant was 
further used in following protein purification steps.  
 
2.6 Protein purification 
 
The first step of the protein purification was an affinity chromatography purification by 
HisTrap HP 5 ml column
105
 (GE HealthCare). The next step was a TEV cleavage of the HisTag by 
TEV (Tobacco Etch Virus) protease. The TEV cleavage followed a second affinity 
chromatography via HisTrap HP 1ml to purify the target protein from the TEV protease, the 
HisTag peptide, uncut protein and other contaminant proteins. At last step gel filtration (size 
exclusion chromatography) was executed in order to produce the most pure protein as possible and 





2.6.1 Affinity chromatography and TEV cleavage 
 
Affinity chromatography was executed by HisTrap HP 5 ml columns in first step of 
purification protocol. HisTrap columns are packed with Ni Sepharose HP (High Performance) 
beads that facilitates to formation of chelate complexes between Ni
2+




Routinely, HisTrap chromatography consists of consecutive steps as column equilibration, 
sample application including washing of unbound proteins, and, finally, sample elution. Äkta 
prime plus Fast Protein Liquid Chromatography (FPLC) system (GE Healthcare) and software 
Unicorn 5.0 (GE Healthcare) was used to perform and analyze the affinity chromatography. 
38 
 
HisTrap HP 5 ml column was connected to a peristaltic pump Pharmacia LKB (model Pump P-1) 
and washed by 3 CV by MilliQ water which was followed by column equilibration by 5 CV of 
binding buffer. Afterwards, the supernatant with the target protein, which has been obtained in the 
cell disruption step described previously, was applied by the pump into the column. The column 
was connect to the Äkta prime plus FPLC system and washed by 5 CV of binding buffer with a 
flow rate of 1 ml/min. The flowthrough was collected in fractions of 5 ml. The column was 
washed with 5% elution buffer, and the (His)6-DYRK1B wt and the mutants were eluted by an 
imidazole gradient (5-100% elution buffer corresponds to 10-500 mM of imidazole) with a 
gradient length of 8-10 CV. 1 ml fraction size was set during running of gradient to collect the 
eluted protein. Based on the chromatogram fractions were chosen to be analyzed by SDS-PAGE.  
In order to cut the (His)6-tag a TEV-protease cleavage step was employed. After the SDS-
PAGE the fraction containing the target protein were pooled and mixed with 500 µl of 2 mg/ml 
TEV. The mixture was transferred to a SnakeSkin Dialysis Tubing with 10kDa molecular weight 
cut-off membrane (Termo Scientific). The membrane tube was carefully closed by clips and 
placed into dialysis buffer with magnetic stirrer o/n at 4  C. After dialysis the sample was poured 
out from the dialysis membrane and placed on ice, meanwhile, a HisTrap HP 1 ml column was 
washed and equilibrated as described for the HisTrap HP 5 ml columns. Depending on the volume 
15 of 20 ml of loading tube were connected to the Äkta prime plus system and sample was loaded 
into the tube by a syringe. The sample was then further injected from the loading tube onto the 
column with a flow rate of 1 ml/min. The flowthrough was collected in 5 ml fractions. The 
proteins were eluted by an imidazole gradient (5-100% elution buffer corresponds to 10-500 mM 
of imidazole) with a gradient length of 35-50 CV. The fraction size during the gradient was 1 ml 
to collect the eluting proteins. Based on the chromatogram fractions were chosen to be prepared as 
samples for the SDS-PAGE. After the SDS-PADE fractions with the target protein were pooled 
and concentrated for gel filtration chromatography.  
 
2.6.2 Gel filtration 
 
HiLoad™ 16/60 Superdex™ 200 column
106
 (GE Healthcare) and the Äkta basic FPLC system 
were employed for gel filtration. The gel filtration was performed with a flow rate of 1 ml/min at 
4  C. The gel filtration column was washed by 1 CV of MilliQ and, after that, equilibrated by 1 CV 
of gel filtration buffer. With the help of syringe, the sample was loaded into a 5 ml loading tube 
connected to Äkta basic FPLC system. The sample was injected through 5 ml tube onto the 




fractions. SDS-PAGE samples were selected based on the chromatogram. After the SDS-PAGE 
the fractions containing the protein of interest were pooled and the concentration of the protein 
was measured by Nanodrop.  
 
2.7 SDS-PAGE  
 
The protein was analyzed by Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) to verify the size, enrichment and the purity of the purified protein. A SDS-PAGE 
was run after each step of the protein purification. 10-, 12- and 15-well Mini-PROTEIN® TGX™ 
gels (BIO- RAD) were used for SDS-PAGE. Sample preparation included the following steps: 
choice of protein fraction based on the chromatogram, mixing of 15 µl of each fraction together 
with 5 µl of 4x NuPAGE LDS sample buffer (Life Technologies), and, finally, all samples were 
boiled at 95  C for 5 min to denature the protein. After denaturing the sample were ready to be 
loaded in the well of the gel. The Mini-PROTEIN
®
 TGX™ gel was vertically oriented in a holder 
and place between two electrodes in an electrophoresis cell. Inner and outer cambers of the 
electrophoresis cell were filled with Tris-Glycine running buffer.  
10 µl of Mark12 protein ladder (Life Technologies) was used as standard to compare the 
molecular weight and loaded into the first well. 15-20 µl of protein prepared as described above 
were loaded in the wells of the Mini gel. The electrophoresis cell was attached to a PowerPac 
Basic power supply (BIO-RAD) and the SDS-PAGE was run at 200 V, 90 mA for 35 min. The 
voltage was kept constant throughout the run. After the electrophoresis was completed the gel was 
rinsed by 100 ml of MilliQ water and boiled for 1-1.5 min. SimplyBlue™ SafeStain (Invitrogen) 
was added to the gel in the volume of 20 ml to cover the gel. The gel was boiled with 
SimplyBlue™ SafeStain for 1-1.5 min and placed on an orbital shaker for 1 hour. Afterwards, 
SimplyBlue™ SafeStain was discarded, and gel was rinse by MilliQ water and kept at room 










The concentration of proteins used in this thesis was measured by the Nanodrop 2000c 
spectrophotometer (Thermo Science)
107
. 2 µl of buffer was used as a blank and 2 µl of protein 
solution was used for measurement of its concentration. The extinction coefficient and molecular 
weight of the proteins used in this thesis were calculated by the on-line tool Protparam at the  
ExPasy webpage
100
 (Table 6).  
 
Table 6. Extinction coefficient and molecular weight of proteins DYRK1B wt and its mutants. 
Protein 
Extinction 
coefficient,    
Molecular weight 
(Da) 
DYRK1B wt 40 340 42 583.8 
DYRK1B L192M 40 340 42 601.8 
DYRK1B Q164K 40 340 42 601.9 
 
 
2.9 Thermoflour Assay for solubility and stability screen 
 
The thermoflour assay can be used as a stability and solubility optimization screens of 
proteins
108
. The principle of the thermoflour assay with a typical melting curve is depicted in 
Figure 12. The assay is based on the monitoring of the melting of protein in the presence of 
fluorescent dye. A gradual increase of the temperature leads to unfolding of the protein and the 
hydrophobic regions/core gets exposed. In this thesis Sypro orange was used as a fluorescent dye. 
The Sypro orange dye binds to internal hydrophobic regions of unfolded protein and this change 
the fluorescence signal which can be monitored. At high temperature the protein undergoes 
aggregation leading to a dissociation of the dye and a decrease of the fluorescence signal. The 
melting temperature is calculated from the slope of the melting curve. It is the point where 50% of 
the protein is denatured. The melting point of a protein can be influenced by different buffers, 
salts, ligands etc. This is used in the thermal shift experiment where the melting point is measured 
in the presence/absence of a ligand of interest or in the presence of different buffers. Higher 
melting temperature compared to the apo-protein indicates a stabilization effect that the ligand has 
to the protein which is connected to binding of the ligand. Lower temperature indicates a 
destabilization effect
109






. Buffers that stabilize the protein most will have the highest melting points. The 
thermofluor method was used to determine optimal buffer condition for DYRK1B. 
 
 
Figure 12. Melting curve of a protein in the thermofluor assay. The figure was modified from the Argonne national laboratory 
web-site111. 
 
The Solubility and Stability buffer screens 1 for DYRK1B buffer optimization was design 
based on the available buffers, experimental data and features of DYRK1B. Concentrations of 
buffers and salts were calculated according to the protocol of the commercially available 
Solubility & Stability screen (Hampton Research)
112
. The Stability and Solubility buffer screen 2 
was designed based on the results of first screen to obtain higher melting temperatures of 
DYRK1B. Both buffer screens were dispensed by the liquid handling system Alchemist 2.6.2 
(Rigaku, Inc.) The reagents of the Stability and Solubility buffer screen 1 and 2 are listed in the 
appendix. The thermoflour assay includes the preparation of a kinase-Sypro orange dye solution 
by adding 1.2 µl of Sypro Orange dye (Sigma Aldrich) to 1.2 ml of DYRK1B wt in buffer A with 
the final kinase concentration kinase of  0.15 mg/ml. Afterwards, 10 µl of DYRK1B-Sypro orange 
dye solution was added to each well of a  48-well PCR microplate. On the next step, 10 µl of each 
condition of Stability and Solubility screen 1 or 2 were mixed with the DYRK1B-Sypro orange 
dye solution in the microplate. To determine the melting point of DYRK1B wt each condition 
from the screen was tested in duplex. The microplate was sealed with transparent sealing film. The 
thermoflour assay was performed by a temperature gradient from 10  C to 90  C (with increments of 
0.3  C) in a MJ Mini personal thermal cycler (BIO-RAD). The data was analyzed by Opticon 
Monitor 3 software.  
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2.10 Enzyme kinetics 
 
The activity of DYRK1B wt and its mutants as well as the inhibitor potency were measured 
by the ATP-regenerative and NADH-consuming assay described by Cook et al.
77
 The method was 
modified for DYRK kinases. In the Cook assay, DYRKtide is exploited as the substrate for DYRK 
kinases. The peptide RRRFRPASPLRGPPK (DYRKtide) contains a serine as a specific 
phosphorylation sites and is recognized by DYRK. The kinase activity assay was measured in a 
Molecular Device SpectraMax M2e plate reader at room temperature. The assay mixture contains 
the following ingredients: 100 mM MOPS (pH 6.8), 10 mM KCl, 10 mM MgCl2, 1 mM 
phosphoenolpyruvate (PEP), 1 mM DYRKtide, 1 mM β-ME, 15 units/ml lactate dehydrogenase, 
10 units/ml pyruvate kinase and 10,7 mM NADH. The Cook assay reaction was composed by 
adding 75 µl of assay mixture, 10 µl of DYRK kinase (concentration range 5-20 µM), 10 µL of 
2560 or 1280 µM ATP with total volume 95 µl. For the Km determination a serial of ATP 
concentration from 50 mM to 4 µM was used. The enzymatic velocity measured in the Cook assay 
is the consumption of NADH and in the loss of absorption at 340 nm. Therefore the velocity has a 
negative slope. As a standard for testing the inhibitors the concentrations of the kinase and ATP 
were adjusted to obtain an initial velocity of around -10 AU/sec. The measurements were done in 
triplex and each individual measurement over a time period of 300 sec. In the case of the Km 
determination shorter time periods were chosen, in particular for the higher ATP concentration, to 
obtain the initial velocity while the curve was still linear. For the screening, all inhibitors were 
tested at a concentration of 20 µM in the reaction mixture. In order to identify IC50 values a serial 
dilution of inhibitor concentrations were used in the range between 20 µM and 4 nM.  
 
2.11 Microscale thermophoresis 
 
Thermophoresis is a phenomenon describing the ability of molecules to move along a 
temperature gradient, which first was described in 1856 by Carl Ludwig
113
. Particularly in 
solutions molecules have the tendency to move away from the high temperature region with a 
dependency of the hydration shell and the solvation entropy of the molecules
114
. The depletion of 
molecules in the region of the elevated temperature compared to the initial thermal conditions 
(  ) can be quantified by the Soret coefficient ST described by following equation
115
 (3) 
    
     




This principle was utilized to develop the microscale thermophoresis (MST) by NanoTemper 
Technologies GmbH (Germany). In the instrument Monolith NT.115 the NanoTemper technology 
employs fluorescence in combination with infrared-laser optics for local heating of the sample in a 
small capillary. The biomolecules are labeled by fluorescence dyes and the fluorescent signal is 
recorded before turning the laser on followed by the fast temperature dependent changes in 
fluorescent intensity when the laser is switch on, and finally the signal returns to the starting point 
in a back diffusion after switching off the laser
116
. The binding of a ligand to a biomolecule 
changes its hydration shell and affects the thermophoretic movement. This principle is used to 
determine binding affinities with high accuracy
117
.  
The interaction of DYRK1B wt with ATP was tested by MST. For detailed Kd analysis 16 
capillaries each with different ATP concentrations were employed in MST. DYRK1B in the 
concentration of 14 µM in buffer D was used for the MST. DYRK1B was labeled with the 
Monolith NT Labeling kit (Cat No. L001). A 2-fold dilution series of ATP was prepared and an 
equal amount of DYRK1B was added to each ATP concentration. Each sample was loaded into a 
MonolithTM hydrophilic capillary through capillary action and then analyzed with the Monolith 
NT.115 instrument.  
 
2.12 Crystallization trials of DYRK1B and DYRK1A 
 
Crystallization trials of DYRK1A and DYRK1B in gel filtration buffer were performed by 
vapor diffusion method
118
. After gel filtration the DYRK kinase was concentrated in an Amicon® 
Ultra-4 centrifugal filter (Merck Millipore) in order to reach the concentration of ~ 7-8 mg/ml 
(DYRK1A) or ~11-13 mg/ml (DYRK1B) (measured by Nanodrop). The apo-protein, and protein 
in the complex with inhibitor were used for the crystallization trials. Routinely, 100 µl of high 
concentrated DYRK kinase was gently mixed with 4 µl of 10 mM inhibitor in DMSO or water 
(final concentration of the inhibitor in the crystallization trials was 400 µM). The commercially 
available crystallization screen JCSG-plus™ (Molecular Dimensions)
119
, Wizard I and II (Emerald 
Bio)
120
 and the in house screen KCSG were used to screen for crystallization conditions. The 
screening was set up by Phoenix protein crystallization robot (Art Robbins Instruments) in 96-
wells sitting drop plates in ratio of 200 nl protein solution and 200 nl of crystallization 
condition
121
. Crystallization trials were performed at room temperature and at 4  C. The hits from 
the screen were selected for further optimization. The conditions from the screen were optimized 
by designing 24-well screens with gradients of precipitants and salts and dispensed by Alchemist 
2.6.2 (Rigaku, Inc.). The crystallization trials were set up by hanging drop method in 24-well 
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crystallization plates with the ratio of 2+2 µl and 2+4 µl of protein solution to reservoir solution 
containing optimized crystallization conditions.  
In the case of DYRK1A an Additive Screen (Hampton Research) was employed
122
. A 96-
deep well block was dispensed by Alchemist 2.6.2 with 900 µl of a crystallization condition found 
in the JCSG-plus™ screen and in each of the well of deep well block 100 µl of each additive 
solution was added and mixed. The 96-well sitting drop plate with new Additive Screen was set 
up by Phoenix protein crystallization robot with the same 200 nl +200 nl ratio of protein solution 
to crystallization condition. The plates were placed at 4  C and room temperature and the drops 
were examined every second day. The conditions with the additives which gave the best crystals 
were further selected to be set up in crystallization trials with 24-well hanging drop plates.  
Crystals were flash frozen with different cryoprotectants in liquid nitrogen in either 30% 
ethylene glycol, paratone, 30% glycerol, 30% PEG400 or 40% PEG3350. The crystals were sent 
to BESSY II at the Helmholtz Zentrum Berlin (Germany) for X-ray data collection. Diffraction 
data was integrated by XDSAPP program
123
 and the crystal structure was solved together with 
Dr. Ulli Rothweiler by molecular replacement with MolRep
124,125
 of the CCP4 software 
package
126,127























3.1 Cloning and mutagenesis 
 
The human DYRK1B gene was originally cloned and characterized by Leder S. et al.
30
.  The 
DYRK1B gene encoding full length protein that was used in this thesis was the Addgene plasmid 
23761
130
 in the vector pDONR223-DYRK1B. 
The original expression clone of the DYRK1B containing amino acid sequence 78-442 was 
mostly expressed in inclusion bodies and had low yield and solubility. Therefore, it was decided to 
create a longer construct by adding several amino acids at the C-terminal end to improve the 
solubility of DYRK1B. The Gateway cloning strategy (Life Technologies) together with 
directional TOPO
®
 cloning (Life Technologies) were used to produce expression clone pEXP17-
hsDYRK1B-KD-451 comprising residues 78-451. The template DNA from plasmid pDONR223-
DYRK1B was amplified in DH5α E. coli, isolated and purified by QIAprep spin Miniprep kit 
(QIAGEN). The concentration of amplified DNA template was 276 ng/µl measured by absorbance 
at 260 nm on a Nanodrop spectrophotometer. To obtain the blunt-end PCR product containing 
desired DYRK1B gene, Phusion polymerase was employed and PCR was performed as described 
in the method section of this thesis.  
Electrophoresis on a 0.7% agarose gel was used to separate the PCR product. The successful 
amplification of DYRK1B construct which has the length of 1153 bp is shown in Figure 13. The 
PCR product was extracted from the 0.7% agarose gel by QIAquick Gel Extraction kit 
(QIAGEN). The concentration of the purified PCR products was measured by Nanodrop. The 
concentration of PCR-I product (lane 5, annealing temperature 70  C) and PCR-II product (lane 8, 
annealing temperature 55  C) were 11.3 ng/µl and 10.3 ng/µl, respectively. Two TOPO
®
 cloning 
reactions, one with each PCR-I product and PCR-II product, were performed to produce the entry 




Figure 13. The results of PCR amplification separated by electrophoresis on a 0.7% agarose gel. Four different annealing 
temperatures were employed during amplification process. Each temperature was run in duplicate. Lanes 1 and 6 are the 1 kb DNA 
Ladder; Lanes 2 and 3 had 50  C annealing temperature;  4 and 5 had 70  C; 7 and 8 had 55  C, 9 and 10 had 67  C.  The thick bands 
between 1 kb and 1.5 kb are the successfully amplified DYRK1B wt PCR products obtained using the pDONR223-DYRK1B 
plasmid as a template. Bands in lanes 5 and 8 marked with a star were selected to proceed with cloning and cut out from the gel. (In 
the figure shown here these bands are already cut out). 
 
pENTR-DYRK1B-451-I and pENTR-DYRK1B-451-II were transformed into One Shot
®
 
Top10 chemically competent E. coli. The plate with the transformed construct containing PCR 
product from the annealing temperature at 70  C did not give any colonies, thus, the first entry 
vector  pENTR-DYRK1B-I  was used to continue the cloning. Three colonies from the plate with 
pENTR-DYRK1B-I plasmid were selected to be amplified. Plasmids were isolated and purified by 
QIAprep spin Miniprep kit (QIAGEN). Three plasmids were sequenced with M13 forward and 
reverse primer using the Big.Dye Terminator v3.1 sequencing kit. The results of sequencing 
showed that one plasmid had the correct insert with the correct N- and C-terminal ends. The 
concentration of the correct pENTR-DYRK1B-451-I vector was 158.7 ng/µl. In the next step, the 
recombination reaction as described in the methods section was performed to produce the 
expression clone: pEXP17-hsDYRK1B-KD-451. 
The recombined vector was transformed into One Shot
® 
Top10 competent E. coli (Life 
Technologies). Two colonies were selected for amplification followed by purification and 
sequencing with T7 forward and reverse primers. Results of the sequencing showed that one 
colony was a positive clone. This plasmid was used for large scale expression of DYRK1B wt and 
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Site-directed mutagenesis was performed using a strategy similar to the QuikChange II site-
directed mutagenesis protocol (Agilent Technologies). The wild-type pEXP17-hsDYRK1B-KD-
451 plasmid was used as a template. Pfu Turbo DNA polymerase was used together with the 
specific primers, described in the section 2.3 p.34, to produce the desired mutants. After the PCR 
amplification the parental plasmids were digested by DpnI endonuclease followed by 
transformation of the new mutated plasmid into XL10 Gold ultracompetent E. coli (Agilent 
Technologies). Two colonies from each transformation were selected to be amplified in mini 
cultures. Plasmids with point-mutations were purified by QIAprep spin Miniprep kit (QIAGEN) 
and sequenced by Big.Dye Terminator v3.1 sequencing kit to verify the mutations. The three 




Figure 14. Results of sequencing DYRK1B L192M, DYRK1B Q164K and DYRK1B C238R mutants. The sequencing 
chromatogram of DYRK1B wt is represented in the lower row. Sequencing chromatograms of DYRK1B L192M, DYRK1B 
Q164K and DYRK1B C238R are depicted on the upper row. The mutated nucleotides are highlighted by vertical black box. 
 
 
3.2 Purification of DYRK1B wt in original phosphate buffer 
 
The purification protocol of the DYRK1B wt was established based on the protocol of the 
close homolog DYRK1A. The kinase domain of DYRK1A was successfully expressed as a 
soluble protein with a good yield of more than 20 mg per liter. Since the two proteins DYRK1A 
and DYRK1B are so similar the same expression and purification protocol was used.  
The pEXP17-hsDYRK1B-KD-451 plasmid was transformed into BL21-CodonPlus(DE3)-
RIL E. coli strain (Agilent Technologies) and expressed in 4 L of TB media. Buffer A (Table 1, 




protein. After sonication followed by separation of soluble fraction of the cell lysate by 
centrifugation, the first step of purification was performed by HisTrap HP 5 ml column (GE 
Healthcare). Routinely, the column was washed, equilibrated and the supernatant was loaded into 
the column by a peristaltic pump. The flow rate of 1 ml/min and pressure limit 0.5 MPa was 
employed during the purification. DYYRK1B wt was eluted on a gradient of 5-100 % (25 -500 
mM Imidazole)  elution buffer B (Table 1, p.27) in 8 CV. The peak corresponding to DYRK1B wt 
had a average value of 200 mAU. DYRK1B wt elutes at aproximatly 50-70% of elution buffer B 
(250-350 mM imidazole), Figure 15, a. The fractions 19, 20, 22, 24, 26, 28, 30, 32, 35, 37 and 38 
were analysed by SDS-PAGE (Figure 15, b). The results of SDS-PAGE shown that fractions 30-
38 contains the DYRK1B wt. Based on the chromatogram and results of SDS-PAGE, the fractions 
32-40 were pooled to conduct the  TEV-cleavage by dialysis in buffer C o/n. 
In order to separate TEV protease, the (His)6-tag peptide, and contaminants from the 
DYRK1B wt protein, a second affinity chromatography by HisTrap HP  1 ml column was used 
(Figure 16, a). Flow rate was set to 1 ml/ min and max pressure was 0.5 MPa. Unbound materials 
are depicted as a flowthrough in the chtomatogram. DYRK1B was eluted by gradient of buffer 0 -
100%  (0-500 mM Imidazole). Fractions 2, 10, 11, 12, 14, 15, 18, 19  and 20 were selected for 
SDS-PAGE. Based on the results of SDS-PAGE (Figure 16, b) the main peak of around 250 
mAU and a concentration of 25% of Buffer B corespended to cleaved DYRK1B wt. The (His)6 -
tag  was successfully cleaved by the TEV protease. The TEV cleavage was confirmed by the 
difference in size of uncleaved band (uc on the Figure 16, b) and cleaved fractions (10, 11 and 
12). Fractions 10, 11 and 12 were pooled and futher used for gel filtration (size exclusion 
chromatography). 
A HiLoad™ 16/60 Superdex™ 200 column was employed for final purification to obtain pure 
protein suitable for kinetic assays and crystallization trails. The sample was eluted with a flow rate 
of 1 ml/min during 1.2 CV. The fractions were collected to 2 ml. The results of chromatography is 
represented in the Figure 17, a. The fractions 33-41 were selected for SDS-PAGE (Figure 17, b). 
The peak in the chromatogram around 60 mAU corresponded to DYRK1B wt. The fractions 36-
41 were pooled and the final concentration was 0.04 mg/ml in 12 ml measured by absorbance at 
280 nm on the Nanodrop which is a final yield of 0.6 mg protein (0.15 mg of protein per liter) 
based on the molar absorbance coefficient (Table 6, p.40). The estimated purity of DYRK1B wt 
was around 98%. The band from SDS-PAGE after gel filtration was cut out and sent to Mass 
Spectrometry. The results of the Mass Spectrometry confirmed that the purified protein is 









Figure 15.  Purification of (His)6 -DYRK1B wt. a) The chromatogram shows the affinity purification of DYRK1B wt by HisTrap 
HP 5ml column. The blue line is the absorbance at 280 nm, the green line is percentage of elution buffer B (0%-100% corresponds 
to 0-500 mM imidazole). The red line is the conductivity. Different peaks in the chromatogram are depicted by arrows. The sample 
was loaded by a peristaltic pump prior to the purification with Äkta prime thus the chromatogram begins with the column wash 
step. b) SDS page of the selected fractions of the chromatogram.  Mark12 in lane 1 was used as marker; the numbers above the 
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Figure 16. Purification of DYRK1B wt after TEV-cleavage. a) The chromatogram shows the affinity purification of DYRK1B 
wt by HisTrap HP 1ml column.The blue line is the absorbance at 280 nm, the green line is percentage of elution buffer B  (0%-
100% corresponds to 0-500 mM imidazole). Different peaks in the chromatogram are depicted by arrows. The red line is the 
conductometry. DYRK1Bwt elutes at an imidazole concentration of approximately 125 mM. b) SDS page of the selected fractions 
of the chromatogram. Mark12 in lane 1 was used as marker, the numbers above the lanes represent the fractions, uc (uncleaved) is 





































           
 
Figure 17. Gel filtration of DYRK1B wt. a) Gel filtration (size-exclusion chromatography) was performed by HiLoad™ 16/60 
Superdex™ 200 column. Flow rate was 1 ml/min. Fraction size was 2 ml. Different peaks in the chromatogram are depicted by 
arrow. The Blue line is the absorbance at 280 nm. b) SDS page of the selected fractions of the chromatogram. Mark12 in lane 1 




























3.3 Thermofluor Assay for Solubility and Stability Screen 
 
The initial protocol, which employed phosphate buffer for the lysing of cells and affinity 
chromatography, showed that the protein had low solubility and the yield was low. The expression 
however was high, so the protein was mostly expressed in inclusion bodies. A fraction of protein 
in phosphate buffer did not bind to the column, probably, because it formed soluble aggregates in 
this buffer. The protein could be concentrated only to 6 mg/ml in gel filtration buffer (buffer D). 
The crystallization trials with commercial screens showed however that the vast majority of the 
drops stayed clear for more than 2 weeks after the crystallization setup. This fact indicates that a 
higher concentration has to be used for the crystallization of protein. Since it was impossible to 
concentrate the protein more than 6 mg/ml in the gel filtration buffer, and because the protein 
precipitated, it was decided to change the buffers for the purification. Thermoflour assay was 
employed to screen for an optimal buffer. The first screen was comprised of 96 conditions 
including five different buffers with a pH range between 5.5 and 8.5, a combination of three 
different salts, and CHAPS as a detergent. The second screen was designed based on the result of 
first one in order to establish the concentration of KCl which will give the highest melting point.  
 Results of the Stability and Solubility screen 1 are represented in the Figure 18. The best 
condition was MES pH 6.5 which improved the melting temperature compared with phosphate by 
10 degrees. In case of the HEPES pH 7.5 buffer, it was observed that the Tm of the protein in 
conditions containing KCl (light blue columns) gave increased melting temperatures compared to 
conditions with alternative alkali salts like LiCl (orange columns) or NaCl (green columns). In 
other cases it was also detected that the presence of KCl in the buffer stabilizes the protein better 
than NaCl or LiCl. In general no extra addition of salt (dark blue columns) was best, but it should 
be kept in mind that all samples contained 250 mM NaCl from the 1:1 mixing with the buffer the 
protein was purified with in the first place (50 mM Na2HPO4 pH 8.0, 500 mM NaCl). The first 
step in the purification of DYRK1B is via the HisTrap columns, therefore, a pH above 7.5 for an 
optimal interaction of the (His)6-tag with the column and high salt concentrations to avoid 
unspecific interactions was desired. Thus, it was decided to design a second screen, where we 










Figure 18. Results of Stabilization and Solubility buffer screen 1. Red column is the starting condition with protein in phosphate 
buffer (50 mM Na2HPO4  pH 8.0, 500 mM NaCl). All samples contain 250 mM NaCl from the starting condition. 50 mM buffer 
without additional salts (dark blue), 50 mM buffer and 400 mM KCl (light blue), 50 mM buffer and 400 mM NaCl (green), 50 mM 
buffer and 400 mM LiCl (orange). Tm is the melting temperature of the protein. The graph shows a representative fraction of the 




























































Stability and Solubility screen 2 was composed of 49 conditions (Appendix) including the 
buffers (50 mM) which gave the best scores in the first run and four different concentrations of 
KCl: 50, 10, 150 and 200 mM. The MES pH 6.0, pH 6.5 and MOPS pH 6.5 buffers showed no 
sensitivity to the KCl concentration. The Tris buffer pH 7.0 showed a decrease in stability with 
higher KCl concentrations. The best hits of Screen 2 were the HEPES buffers pH 7.5 and pH 8.0 
which showed an increase in stability with higher KCl concentrations compared to the buffer 
without KCl. The results are summarized in the Figure 19. The biggest improvement was seen for 
the HEPES buffer at pH 8.0 where the addition of 50 mM KCl improved the melting temperature 
by 6.7 degree from 38.8 to 45.5 compared to the KCl free buffer which was better than the MES 




Figure 19. Results of the Stability and Solubility Screen 2 by thermoflour assay. The graph shows a representative fraction of 
the 49 condition in Stability and Solubility screen 2. The red column indicates the starting condition with the phosphate buffer (50 
mM Na2HPO4 pH 8.0, 500 mM NaCl). All samples contain 250 mM NaCl from the starting condition. The best stabilization effect 
by KCl is seen for HEPES buffer (dark green columns). The values of the KCl-free buffer conditions from Stability and Solubility 















































The results of Thermofluor of Stability and Solubility Screen 2 shown also that the addition 
KCl salt to MES pH 6.5 did not increasing the melting point of DYRK1B. In contrast, HEPES 
buffer pH 8.0 with different KCl concentrations increased the melting point by about 12.5  C 
compared to the original phosphate buffer (Figure 20).  DYRK1B wt is significantly more stable 
in every tested buffer than the buffer used so far for the purification. Since the first step of the 
purification is affinity chromatography which requires the (His)6-tag to be charged the HEPES 





Figure 20. Comparison of thermoflour assay results of phosphate buffer pH 8.0 and HEPES buffer pH 8.0 with 50 mM KCl 
of Screen 2. Fluorescence on the Y-axis. Temperature in  C on the X-axis. a) Melting point of protein in Phosphate buffer pH 8.0 is 
33  C. b) Melting point of DYRK1B wt  in condition containing 50 mM HEPES buffer pH 8.0 and 50 mM KCl is 46  C. The figures 
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3.4 Purification of DYRK1B Q164K using HEPES buffer  
 
The DYRK1B Q164K mutant was designed and produced for crystallization trials. DYRK1B 
Q164K was initially purified using the same protocol as for DYRK1B wt employing phosphate 
buffer. The use of phosphate buffer for purification of DYRK1B Q164K presented the same issues 
as for DYRK1B wt: low yield and solubility, weak binding to the HisTrap column and expression 
in inclusion bodies. The result of the Stability and Solubility screen 1 and 2 by thermofluor assay 
shows that the highest melting temperature for DYRK1B wt was a buffer containing 50 mM 
HEPES pH 8, 50 mM KCL and 250 mM NaCl. Large scale purification of DYRK1B Q164K was 
therefore tested in the new buffer because we were interested to produce this mutant at high yield, 
purity and solubility for crystallization trails.  
Following the procedure described in the methods section, DYRK1B Q164K was purified in a 
similar way to DYRK1B wt with phosphate buffer, and for comparison with the HEPES buffer. 
The chromatogram of DYRK1B Q164K (Figure 21, a) and the following SDS-PAGE (Figure 21, 
c) represents the results of the affinity chromatography performed by HisTrap HP 5 ml column in 
phosphate buffer. To show the positive impact of HEPES buffer and for direct comparison to the 
phosphate the chromatogram (Figure 21, b) and SDS-PAGE (Figure 21, d) of DYRK1B Q164K 
are shown for the purification in HEPES buffer.  
In the case of phosphate buffer, the flow-through and fractions 5, 15, 16, 18, 19, 21, 23, 24, 
25 and 26 were selected to be analyzed by SDS-PAGE. The result of SDS-PAGE shows that 
DYRK1B Q164K is present in the fractions 21-26. The peak on the chromatogram with 
absorption of around 200 mAU corresponds to the DYRK1B Q164K. DYRK1B Q164K was 
eluted at around 60% of Buffer B (300 mM imidazole).  
In the case of HEPES buffer, flow through and fractions 6, 19, 20, 22, 24, 25, 26, 27, 28 and 
29 were selected for SDS-PAGE. The result of SDS-PAGE shows that fractions 19-28 contain the 
DYRK1B Q164K. These fractions correspond to a peak about 825 mAU in chromatogram which 
is significantly higher compared to the one with phosphate buffer. The maximum of DYRK1B 
Q164K was eluted by 55 % of buffer G (275 mM imidazole). Although it is poorly visible on the 
SDS-PAGE (Figure 21, d), the flow-through does not contain DYRK1B Q164K indicating a good 
binding of the protein to the column, and later experiments confirms that the protein in HEPES 
buffer binds better to the column compared with the phosphate buffer.  
The comparison of the two chromatograms allows the conclusion that HEPES buffer has 
positive impact on the solubility, binding and yield of DYRK1B Q164K compared to phosphate 




In the case of the purification with phosphate buffer, fraction 22-30 were pooled together with 
TEV protease and dialyzed in buffer C to cleave the (His)6-tag o/n. In the case of HEPES buffer, 
fractions 22-34 were selected for TEV cleavage in buffer H o/n. 
The second affinity chromatography step was carried out after TEV cleavage similar to the 
protocol for DYRK1B wt. The chromatogram of DYRK1B Q164K in phosphate buffer is depicted 
in the Figure 22, a. Fractions 6, 10, 17, 18, 19, 20, 21, 22, 24 26 were selected for SDS-PAGE 
(Figure 22, c).  In the case with phosphate buffer, based on the SDS-PAGE the peak with the 
value around 280 mAU corresponds to the DYRK1B Q164K. The maximum of protein was eluted 
at 20% of elution buffer B (100 mM imidazole).  
The chromatogram of DYRK1B Q164K in HEPES buffer is represented in the Figure 22, b. 
The fractions 2, 9, 10, 11, 12, 13, 14, 15, 18 and 20 were selected for SDS-PAGE (Figure 22, d). 
Based on the results of SDS-PAGE the main peak with a value of around 725 mAU corresponds 
to the DYRK1B Q164K. Protein was mostly eluted at 16 % of buffer F (80 mM imidazole). In 
both cases TEV cleavage was successful which is confirmed the size difference of cleaved and 
uncleaved samples on the SDS-PAGE (uc in the Figure 22, c and d). 
In the last step of the purification, a gel filtration was performed using a HiLoad™ 16/60 
Superdex™ 200 column. Buffer D was used as a gel filtration buffer in the protocol prior to the 
buffer optimization. The chromatogram of the gel filtration with buffer D is shown in Figure 23, 
a. Fractions 21, 27, 32, 34, 36, 37, 38, 40, 44 and 49 were selected for SDS-PAGE. The result of 
the SDS-page (Figure 23, c) shows that fractions 34-40 contain DYRK1B Q164K, therefore, the 
peak in the chromatogram with the value of 20 mAU corresponds to the DYRK1B Q164K mutant. 
The fractions 34-39 were pooled and the final concentration was 0.04 mg/ml in 12 ml measured 
by Nanodrop which is a final yield of 0.6 mg protein (0.15 mg of the protein per liter of media).  
After buffer optimization, the gel filtration was performed using the buffer G as a gel 
filtration buffer. The chromatogram of the gel filtration is represented in the Figure 23, b. 
Fractions 30, 31, 33, 34, 35, 36, 37, 38, 39 and 40 were selected for SDS-PAGE. The results of 
SDS-PAGE are shown in the Figure 23, d. Fractions 30-40 contain DYRK1B Q164K. The peak 
in the chromatogram with the value of around 206 mAU corresponds to DYRK1B Q164K. The 
fractions 31-40 were pooled and final concentration was 0.43 mg/ml in 20 ml measured by 
Nanodrop which is a final yield of 8.6 mg protein (2.15 mg of the protein per liter of media).  
Thus, buffer change from phosphate buffer to the HEPES buffer improved the yield of 







a)                                                                b)  
 
c)                                                                                  d) 
 
 
Figure 21.  Purification of (His)6 - DYRK1B Q164K. a) The chromatogram shows the affinity purification of DYRK1B 
Q164K by HisTrap HP 5ml using phosphate buffer. b) The chromatogram shows the affinity purification of DYRK1B 
Q164K by HisTrap HP 5ml using HEPES buffer. The blue line is the absorbance at 280 nm, the green line is 
percentage of elution buffer B (0%-100% corresponds to 0-500 mM imidazole). Absorbance in mAU is shown on the 
Y-axis, min (blue) is shown under the X-axis. The number of fraction is shown above the X-axis. The red line is the 
conductivity. Different peaks in the chromatogram are depicted by arrows. The sample was loaded by a peristaltic 
pump prior to the purification with Äkta prime thus the chromatogram begins with the column wash step. b) SDS 
page of the selected fractions of DYRK1B Q164K in phosphate buffer. Fractions 21-26 contain DYRK1B Q164K. c) 
SDS page of the selected fractions of DYRK1B Q164K in phosphate buffer. Fractions 19-29 contain DYRK1B 
Q164K. Mark12 in lane 1 was used as marker; the numbers above the lanes represent the fractions. The bands located 
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a)                                                                           b) 
 
c)                                                                            d) 
 
 
Figure 22. Purification of DYRK1B Q164K after TEV-cleavage. a) The chromatogram shows the affinity purification of 
DYRK1B Q164K by HisTrap HP 1ml column using phosphate buffer. b) The chromatogram shows the affinity purification of 
DYRK1B Q164K by HisTrap HP 1ml column using HEPES buffer. The blue line is the absorbance at 280 nm, the green line is 
percentage of elution buffer (0%-100% corresponds to 0-500 mM imidazole). Absorbance in mAU is shown on the Y-axis, min 
(blue) is shown under the X-axis. The number of fraction is shown above the X-axis. The red line is the conductivity. Different 
peaks in the chromatogram are depicted by arrows. The sample was loaded by a peristaltic pump prior to the purification with Äkta 
prime thus the chromatogram begins with the column wash step. b) SDS page of the selected fractions of DYRK1B Q164K in 
phosphate buffer. Fractions 18-22 contain DYRK1B Q164K. c) SDS page of the selected fractions of DYRK1B Q164K in HEPES 
buffer. Fractions 10-15 contain DYRK1B Q164K. Mark12 in lane 1 was used as marker; the numbers above the lanes represent the 
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a)                                                                                   b) 
 
c)                                                                                     d) 
 
Figure 23. Gel filtration(size-exclusion chromatography) of DYRK1B Q164K. a) The chromatogram shows the purification of 
DYRK1B Q164K by HiLoad™ 16/60 Superdex™ 200 column using buffer D (before the buffer optimization). b) The 
chromatogram shows the purification of DYRK1B Q164K by HiLoad™ 16/60 Superdex™ 200 column using buffer G (optimized 
buffer). Flow rate was 1 ml/min. Fraction size was 2 ml. DYRK1B Q164K peak in the chromatogram are depicted by arrow. The 
Blue line is the absorbance at 280 nm. b) SDS page of the selected DYRK1B Q164K fractions of the chromatogram in the buffer 
D. Fractions 34-40 contain DYRK1B Q164K. c) SDS page of the selected  DYRK1B Q164K fractions of the chromatogram in the 
buffer G. Fractions 31-40 contain DYRK1B Q164K. Mark12 in lane 1 was used as marker, the numbers above the lanes represent 
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3.5 Purification of DYRK1B L192M 
 
The transformation, expression and purification protocol of DYRK1B L192M mutants was 
similar to those described for DYRK1B wt and DYRK1B Q164K. DYRK1B L192M mutant was 
expressed in 2l of TB media. Äkta prime plus FPLC system was employed to perform the affinity 
chromatography with HisTrap HP 5ml column.  Buffer E was used as a binding buffer and protein 
was eluted by gradient of elution buffer G with the length of 8 CV and target concentration of 
buffer F 500 mM imidazole. The chromatogram of DYRK1B L192M purification is represented in 
Figure 24, a. Flow through and fractions 14, 16, 17, 18, 20, 22, 25, 26, 27, 28, 29, 30 and 32 were 
selected for SDS-PAGE. The result of SDS-PAGE gel is shown in the Figure 24, b. Fractions 25-
32 contain DYRK1B L192M. DYRK1B L192M had a peak with the value of 250 mAU and 
eluted at 65 % of buffer F corresponding to the 325 mM of imidazole. Based on the chromatogram 
and SDS-page the fractions 25-34 were pooled, mixed with TEV protease dialyzed in the buffer G 
o/n. The TEV cleavage was followed by a second affinity chromatography step using a HisTrap 
HP 1 ml column. The chromatogram is shown in Figure 25, a. Buffer E and buffer F were used as 
binding and elution buffers, respectively. Flow through and fractions 12, 13, 14, 15, 16, 17, 18, 19, 
20 and 21 were run on SDS-PAGE, represented in Figure 25, b. The peak on the chromatogram 
around 146 mAU and 34% of buffer F (170 mM imidazole) corresponds to the DYRK1B L192M 
confirmed by SDS-PAGE.  The TEV cleavage was successfully executed since the bands from 
uncleaved fraction (uc on the SDS-PAGE figure) and band with cleaved DYRK1B L192M have 
different sizes that can be clearly seen on the SDS-PAGE figure. Fractions 11-15 were pooled 
together to continue the purification of the kinase by gel filtration. Gel filtration was the last step 
in purification protocol of DYRK1B L192M. The gel filtration was performed as previously 
described for DYRK1B wt and Q164K mutant. β-ME has a short half-life of 8.5 h
131
  and has to 
be added fresh to the gel filtration buffer. However, the fresh β-ME was not added to the gel 
filtration buffer G while performing the last purification step of L192M. The chromatogram of gel 
filtration of DYRK1B L192M is shown in the Figure 26, a. There are three peaks in the 
chromatogram. The SDS-PAGE (Figure 26, b) shows that the first peak does not contain L192M 
mutant, but two other peaks contain the L192M mutant. Comparison with a molecular weight 
standard for the gel filtration column identifies these two peaks as a monomer and dimer of 
DYRK1B. This was further verified by mass spectrometry were samples from both peaks were 
identified as DYRK1B. The fractions 34-44 were pooled and the final concentration was 0.06 





      b) 
 
 
Figure 24. Purification of (His)6 -DYRK1B L192M. a) The chromatogram shows the affinity purification of DYRK1B L192M 
by HisTrap HP 5ml column. The blue line is the absorbance at 280 nm, the green line is percentage of elution buffer F (0%-100% 
corresponds to 0-500 mM imidazole). The red line is the conductivity. Different peaks in the chromatogram are depicted by arrows. 
The sample was loaded by a peristaltic pump prior to the purification with Äkta prime thus the chromatogram begins with the 
column wash step. b) SDS page of the selected fractions of the chromatogram.  Mark12 in lane 1 was used as marker; the numbers 
above the lanes represent the fractions.  Fractions 30-38 contain DYRK1B L192M. The bands located between 55.4 and 36.5 kDa 
corresponded to DYRK1B L192M. 
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Figure 25. Purification of DYRK1B L192M after TEV-cleavage. a) The chromatogram shows the affinity purification of 
DYRK1B L192M by HisTrap HP 1ml column. The blue line is the absorbance at 280 nm, the green line is percentage of elution 
buffer F (0%-100% corresponds to 0-500 mM imidazole). Different peaks in the chromatogram are depicted by arrows. The red 
line is the conductometry. DYRK1B L192M elutes at imidazole concentration of approximately 170 mM. b) SDS page of the 
selected fractions of the chromatogram. Mark12 in lane 1 was used as marker, the numbers above the lanes represent the fractions, 
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Figure 26. Gel filtration of DYRK1B L192M. a) Gel filtration (size-exclusion chromatography) was performed by HiLoad™ 
16/60 Superdex™ 200 column. Flow rate was 1 ml/min. Fraction size was 2 ml. DYRK1B L192M peakes in the chromatogram are 
depicted by arrow. The blue line is the absorbance at 280 nm. b) SDS page of the selected fractions of the chromatogram. Mark12 
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3.6 DYRK1B C238R purification 
 
DYRK1Q C238R possesses the mutation in the catalytic motif HCD. The transformation of 
the plasmid was performed following the protocol of DYRK1B wt. Buffer A was used as a 
binding buffer and buffer B was used as elution buffer because expression of C238R mutant was 
done before buffer optimization. The C238R mutant was expressed in 2 L of TB media. HisTrap 
HP 5 ml column was used for affinity chromatography. The chromatogram of the first purification 
step is shown on the Figure 27, a. Fractions 1, 5, 20, 25, 28, 30, 32, 34, 35, 37 and 40 were 
selected for SDS-PAGE. Based on the SDS PAGE picture the fractions 28-40 contain C238R 
mutant (Figure 27, b). DYRK1B C238R peak in the chromatogram corresponds to the value of 65 
mAU and 66% of elution buffer B (330 mM imidazole). Fractions 30-40 were pooled together.  
Unfortunately the low yield of protein after purification made it impossible to further purify this 
mutant. The band was cut out from the gel and sent to the mass spectrometry facilities for 
verification. 
Mass spectrometry indicates that majority of protein is not phosphorylated at YQY motif. The 
kinase was tested for an activity by the Cook assay. The C238R mutant was not active. However, 
the amount of the kinase might have been too low and the presence of imidazole in the elution 
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Figure 27. Purification of (His)6 -DYRK1B C238R. a) The chromatogram shows the affinity purification of DYRK1B C238R by 
HisTrap HP 5ml column. The blue line is the absorbance at 280 nm, the green line is percentage of elution buffer B (0%-100% 
corresponds to 0-500 mM imidazole). The red line is the conductivity. Different peaks in the chromatogram are depicted by arrows. 
The sample was loaded by a peristaltic pump prior to the purification with Äkta prime thus the chromatogram begins with the 
column wash step. b) SDS page of the selected fractions of the chromatogram. Mark12 in lane 1 was used as marker; the numbers 
above the lanes represent the fractions. Fractions 32-40 contain DYRk1B C238R. The bands located between 55.4 and 36.5 kDa 
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3.7 Inhibitor screen by the Cook assay 
 
Harmine and 49 inhibitors provided by a private pharmaceutical company were tested for 
DYRK1A and DYRK1B wt. The inhibitor screen was performed by an activity-based ATP-
regenerative NADH-consuming assay (Cook assay
77
). Routinely, a “quick” screen for the best 
inhibitors was performed by testing the inhibitors at concentration of 20 µM in the reaction 
mixture with 256 µM of ATP. In the screen the inhibitors were compared according to the 
remaining activity of the kinases. The remaining activity was calculated in percentage by dividing 
the value of the negative slope of the kinase with inhibitor by the negative slope of kinase without 
inhibitor. The results of the inhibitor screen for the 50 inhibitors sorted by their rank for 
DYRK1A wt and DYRK1B wt are summarized in Table 7 (a bar chart of the 50 inhibitors sorted 

















Table 7. Comparison of inhibitors for DYRK1A wt, DYRK1B wt. *Data for DYRK1A were kindly provided by Dr. Ulli 
Rothweiler.   











1 harmine 0 1 Inh 47 6.0 
2 Inh 07 0 2 harmine 12.4 
3 Inh 14 0 3 Inh 04 13.9 
4 Inh 31 1.6 4 Inh 41 17.0 
5 Inh 12 2.9 5 Inh 27 19.9 
6 Inh 47 9.3 6 Inh 45 20.1 
7 Inh 32 9.9 7 Inh 31 21.9 
8 Inh 45 13.9 8 Inh 07 25.2 
9 Inh 04 14.9 9 Inh 12 25.8 
10 Inh 02 16.2 10 Inh 48 25.9 
11 Inh 09 19.6 11 Inh 14 30.6 
12 Inh 08 20.3 12 Inh 08 33.9 
13 Inh 27 23.8 13 Inh 02 36.2 
14 Inh 41 24.6 14 Inh 25 38.2 
15 Inh 42 31.3 15 Inh 32 40.2 
16 Inh 03 34.2 16 Inh 33 42.3 
17 Inh 30 34.5 17 Inh 26 48.7 
18 Inh 21 34.5 18 Inh 42 49.5 
19 Inh 33 37.5 19 Inh 39 51.9 
20 Inh 25 41.9 20 Inh 49 52.6 
21 Inh 22 42.9 21 Inh 22 56.5 
22 Inh 01 45.5 22 Inh 03 59.9 
23 Inh 48 46.9 23 Inh 15 60.8 
24 Inh 35 52.0 24 Inh 44 61.3 
25 Inh 50 52.1 25 Inh 50 67.3 
26 Inh 39 55.0 26 Inh 09 68.4 
27 Inh 29 57.0 27 Inh 36 68.7 
28 Inh 49 57.7 28 Inh 13 69.4 
29 Inh 24 61.9 29 Inh 11 73.1 
30 Inh 10 64.5 30 Inh 43 74.7 
31 Inh 17 65.6 31 Inh 01 76.3 
32 Inh 13 66.1 32 Inh 23 75.1 
33 Inh 36 66.3 33 Inh 40 79.0 
34 Inh 44 67.2 34 Inh 20 81.1 
35 Inh 26 70.4 35 Inh 37 81.3 
36 Inh 28 73.2 36 Inh 35 81.9 
37 Inh 11 74.9 37 Inh 38 83,3 
38 Inh 43 75.2 38 Inh 06 85.5 
39 Inh 20 76.2 39 Inh 34 88.1 
40 Inh 06 76.9 40 Inh 30 88.2 
41 Inh 18 79.1 41 Inh 05 89.7 
42 Inh 15 79.9 42 Inh 21 91.0 
43 Inh 23 80.0 43 Inh 18 93.8 
44 Inh 38 82.1 44 Inh 19 94.2 
45 Inh 40 83.0 45 Inh 24 97.1 
46 Inh 19 84.0 46 Inh 28 97.3 
47 Inh 37 85.4 47 Inh 17 97.9 
48 Inh 34 90.0 48 Inh 29 99.0 
49 Inh 05 92.5 49 Inh 46 100.0 




In order to investigate the effect of mutation in the hinge region to the binding with inhibitors 
the DYRK1B L192M mutant was tested with the 5 best inhibitors of DYRK1A wt and DYRK1B 
wt at the same assay conditions (Table 8). 







1 harmine 3.6 
2 Inh 7 6.4 
3 Inh 47 8.4 
4 Inh 31 10.3 
5 Inh 14 14.6 
6 Inh 4 14.6 
7 Inh 12 15.0 
8 Inh 27 15.3 
9 Inh 41 30.3 
 
The results comparing the effects of inhibitors on mutant of DYRK1B are summarized in 
Table 9  and Figure 28. Most of the inhibitors (5 out of 9) inhibit DYRK1A wt better than 
DYRK1B wt with the L192M mutant in between. Two inhibitors follow no clear trend. Two 
inhibitors did not distinguish between the three DYRKs and showed the same inhibition towards 


























Inhibitors better for DYRK1A wt 
Harmine 0 3.8 6 
Inh 07 0 6.4 25.2 
Inh 14 0 14.6 30.6 
Inh 31 1.8 10.3 21 
Inh 12 2.9 15.3 25.8 
Inhibitors without any trends 
Inh 41 24.6 30.3 17 
Inh 27 23.8 15.3 19.9 
Inhibitor that does not distinguish between the DYRKs 
Inh 04 14.9 13.9 14.6 
Inh 47 9.3 8.4 6.0 
       
 
                   
































3.8 Enzyme kinetics of DYRK1B wt, DYRK1B L192M and DYRK1A. 
 
The inhibitors tested are designed to be ATP-competitive. In order to calculate the Ki value 
(equation (1)) for the inhibitors we need to study enzyme kinetics and determine Km value, i.e. 
Michaelis-Menten constant for ATP, for each kinase of interest. The Km value describes how 
strongly the ATP binds to the kinases. To determine the Km value, a serial of ATP concentrations 
were used in the Cook assay to measure the reaction velocity.  The experiments were performed in 
triplicate with each dilution of ATP in the range from 50 mM to 4 µM. The data were analyzed by 
GraphPad software (Figure 29) and summarized in the Table 10. 
 
 
Figure 29. Michaelis-Menten plots. a)  DYRK 1B  wt,  b) DYRK1A wt, c) DYRK1B L192M 
 




Kinase Km, µM Vmax, AU/sec 
DYRK1A wt 118.5 ± 7.8 µM 51.5 ± 1.0 
DYRK1B wt 80.7 ± 2.7 µM 100.7 ± 0.9 






The experimental data allow the conclusion that all three kinases have different affinities for 
ATP. To be exact, DYRK1B wt has highest affinity to ATP based on the lowest value of Km 
compared to DYRK1A wt and DYRK1B L192M. DYRK1B L192M mutant has a significantly 
higher Km value compared to the wt kinases. If correct, it may indicate that other factors in spite of 
the mutation in the hinge region have a greater influence to the binding affinity of ATP than the 
simple sequence alignment of DYRK1A and DYRK1B would have suggested. 
 
3.9 Ki determination for kinase inhibitors. 
 
The screening of inhibitors was performed to determine the strongest inhibitors from the set 
of 50 inhibitors at a fixed concentration. Based on the results of the screening, inhibitors which 
showed the lowest remaining activity were selected for a more precise determination of the 
inhibition potency. For this purpose the Cook assay was employed for some selected inhibitors in 
serial dilutions (concentration in a range from 20 µM to 4 nM) enabling IC50 value determination 
followed by a Ki calculation using the Cheng-Prusoff equation (1). Routinely, assay trials with all 
kinases were performed at ATP concentrations of 128 or 256 µM and kinase concentrations in a 
range between 0.05 and 0.2 µM in order to obtain a negative slope value of around -10 AU/s. 
Measurements were performed in triplicate for each of the inhibitor concentrations. It was decided 
to select Inh 04, Inh 07, Inh 14, Inh 47 and harmine for IC50 determination and Ki calculation 
















                   
 





IC50= 1,7 µM 
b) 
IC50= 0,88 µM 
c) 
IC50= 1,6 µM 
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In order to compare the effect of mutation on the binding with the inhibitor harmine was 
selected for DYRK1B L192M to determine the IC50 value (Figure 31). 
 
Figure 31. Dose-response curve of IC50 determination for DYRK1B L192M with harmine. 
The inhibitor PKC412 was discovered from the crystallization trial for DYRK1A wt with 
commercially available inhibitors. The binding strength of PKC412 was determined for DYRK1A 
wt, DYRK1B wt and DYRK1B L192M mutant. The dose-response curves for PKC412 for all 
three targets are represented on the Figure 32. 
 
 Figure 32. Dose-response curve for PKC412 inhibitor, a) DYRK1A wt, b) DYRK1B wt, c) DYRK1B L192M. Data for 
DYRK1A was kindly provided by Dr. Ulli Rothweiler. 
b) 
IC50= 66 nM 
a) 
IC50= 59 nM 
c) 
IC50= 163 nM 




The Ki value was calculating using the equation (1) using ATP concentrarion and Km value. 
The IC50 value and calculated Ki for inhibitors and DYRKs were summurized in the Table 11. 
 
 












The Ki values are indicators for the potency of an inhibitor. A smaller value of Ki indicates a 
stronger inhibition. The Ki calculation shows that the best inhibitor for DYRK1B wt was the 
commercial inhibitor PKC412. On the second place is the inhibitor harmine. The inhibitors from 
the private pharmaceutical company, Inh 04 and 47, were the best from the set of 50 inhibitors, 
however, they are two times weaker than harmine and 25 times weaker than PKC412. The 
DYRK1B L192M has around 6 time higher Ki value for PKC412 compared to DYRK1B wt and 
DYRK1A wt. The comparison of the Ki value for harmine between the DYRK1B wt and 
DYRK1B L192M shows that the Ki value of DYRK1B L192M is also two times higher than for 
DYRK1B wt. If correct, this is mainly due to the significant higher Km value for DYRK1B 
L192M compared to DYRK1A and DYRK1B wt. The IC50 values for the inhibitor harmine are 
with 876 nM (DYRK1B) and 656 nM (DYRK1B L192M) in the same magnitude with a slight 





   Kinase Inhibitor ATP, µM IC50, nM Ki, nM 
DYRK1A wt PKC412 128 59 28.4 
DYRK1B wt PKC412 128 66 25.4 
DYRK1B L192M PKC412 128 163 149.4 
DYRK1B wt harmine 128 876 337.2 
DYRK1B L192M harmine 128 656 601.1 
DYRK1B wt Inh 4 128 1624 624.6 
DYRK1B wt Inh 7 256 4108 978.1 
DYRK1B wt Inh 14 256 5549 1321.2 
DYRK1B wt Inh 47 128 1780 684.6 
76 
 
3.10 Microscale thermophoresis  
 
The microscale thermophoresis was used to determine a Kd value of ATP towards the 
DYRK1B wt. 16 capillaries with the serial twofold dilutions of ATP, constant buffer 
concentration and concentration of DYRK1B were employed during the experiment. An affinity 
of 78 μM could be derived (Figure 33). 
 
 
Figure 33. Microscale thermophoresis traces and back diffusion analysis of the interaction between DYRK1B wt and 
ATP.  
 
3.11 Crystallization of DYRK1B wt and DYRK1B Q164K 
 
DYRK1B wt and DYRK1B Q164K were obtained in large enough amounts to proceed with 
crystallization trials either as apo-proteins, or in complex with inhibitors selected from the 
inhibitor kinase activity screen: either commercially available inhibitors, or inhibitors from the 
company. The commercially available crystallization screens (e.g. JCSG plus, Wizard) were 
employed to screen for crystallization conditions at different concentrations of protein, 
temperatures and ratios of protein solution to reservoir solution. The promising hits from the 
crystallizations screen were chosen for further optimizations but, unfortunately, the control tests, 
(when the protein solution was excluded from the crystallization experiment), showed that the 
inhibitors themselves crystallized under these selected conditions, even at low concentration 
(around 400 µM), and therefore gave false positive hits. One condition from the in-house KCSG 
crystallization screen (comprising 2 M ammonium sulfate, 0.1 M sodium cacodylate pH 6.5 and 




for data collection but the first diffraction image contained only a few strong diffraction spots that 
indicate the crystallization of a small molecule, most probably the inhibitor. Unfortunately neither 
DYRK1B wt nor DYRK1B Q164K obtained for the crystallization trials crystallized - neither as 
an apo-protein nor in the complex with inhibitors (commercial available or from the kinase 
inhibitor screen).  
 
3.12 Crystallization of DYRK1A 
 
Repeating the published crystallization conditions for DYRK1A did not give crystals with the 
company‟s inhibitor. Therefore a JCSG-plus™ screen was used in a co-crystallization trial with 
DYRK1A and inhibitor 4. The screen gave a hit containing 0.2 M NaSCN and 20% PEG 3350. 
This condition was used for optimization with gradient of 16-25% PEG 3350 and 0.1-0.3 M 
KSCN or NaSCN. The condition with 16% PEG 3350 with 0.1 M KSCN gave the best hits and 
was chosen to run an additive screen, which gave hits with 0.1 M NaCl, 0.1 M KCl, 0.1 M LiCl 
and to minor extent with other salts of alkali halide. 
The hits from additives were added to the crystallization screens. The trials were performed at 
room temperature and 4  C. However, it was observed that at room temperature the crystal grows 
larger, so it was decided to continue to crystallize the protein at the room temperature. The final 
crystallization condition for DYRK1A with PKC412 that gave the best crystal, was 100 mM 
KSCN, 50 mM LiCl, 10-16 % PEG3350. For the crystallization by hanging drop, the 
protein/inhibitor mixture was then mixed 1:1 with the crystallization solution. Octahedral crystals 
appeared within 5 days at the room temperature (Figure 34). The data collection showed that a 
suitable cryoprotectant was 30% ethylene glycol, while N-paratone did not cryoprotect the crystals 













   a)                                                                        b) 
         
 
Figure 34. Crystal of DYRK1A in complex with PKC412. a) octahedral form of crystal, b) bundle of parallel twisted crystals. 
      
 
 
First two diffraction images were taken at 90 degree apart to determine the space group and 
strategy of data collection (Figure 35). The crystal diffracted to 2.6 Å and the diffraction data was 
integrated by XDSapp to calculate the structural factors and convert them in a *.mtz file. The 
structure was solved by molecular replacement method in Molrep, refined by Refmac5 (CCP4 
package) and Phenix. The crystallographic data and model statistics are summarized in the Table 
12. 
 
     a)                                                                              b) 
 





The crystal structure contains one DYRK1A tetramer as an asymmetric unit with the four 
individual DYRK1A molecules related to each other by three perpendicular twofold rotation axes, 
as it was previously described in the DYRK1A structures 3ANQ and 3ANR
16
 (Figure 36).  
 








Table 12. Crystallographic data and model statistics. 
DATA COLLECTION  
Synchrotron radiation BESSY II 14.1 
Detector Pilatus 6M 
Wavelength, Å 0.918409 
Number of crystals used 1 
Number of frames 360 
Oscillation range / frame 0.5 
DIFFRACTION DATA  
Space group P212121   (19) 
Unit cell parameters, Å 87.76, 87.90, 229.92 
Protein molecules in asymmetric unit 4 
Number of measurements 359740 
Unique reflections 55625 
Resolution Range, Å (final shell) 48.251-2.597 (2.664-2.597) 
Completeness (final shell) 99.6 (98.6) 
Mosaicity 





Resolution limits, Å (final shell) 48.251-2.597 (2.664-2.597) 
Number of used reflections 52841 
Percentage observed 99.7 % 
Percentage of free reflections 5.0 % 
Number of protein atoms 11036 
Number of heterogen atoms 176 
Number of water 223 
R factor overall/free  20.76 % / 24.76 % 
Overall figure of merit 0.871 
RMS bonds/angles 0.0064 Å / 1.292 


















The DYRK1A kinase domain follows the same structural arrangement as the other known 
DYRK1A structures
16,53,132
 with the typical kinase fold and the tyrosine Y321 is phosphorylated in 
the structure (Figure 37).  
 




Figure 37. The overview of DYRK1A in the complex with PKC412. a) Overview over the structural elements b) key motifs and 
residues of the kinase. 
 
PKC412 is clearly visible in the electron density map and with an exception of the phenyl 
ring, the coverage is nearly complete (Figure 38). PKC412 is bound to the ATP pocket via two 
hydrogen bonds made by the amine and ketone group in the 2-one-3-pyrroline head group of 
PKC412 to the hinge amino acids E239 and L241. Due to a lack of any hydrogen acceptor or 
donor on the other side of the PKC412, there is no interference with the catalytic lysine K188 as 
described in previous DYRK1A/inhibitor structures
16
 and the main binding of PKC412 is via 





Figure 38. Binding of PKC412 to DYRK1A. The omit map (without PKC412) calculated shows the electron density coverage for 
PKC412. The DYRK1A and PKC412 molecule represented in stick are after final refinement. 
 
 
Figure 39. Stereo image of PKC412 bound to DYRK1A. Hydrogen bonds are made to the backbone atoms of E239 and L241. 
However most of the interactions are via hydrophobic residues. The catalytic Lysine K188 does not participate in the binding of 
PKC412.   
 
 
The four individual chains in the asymmetric unit are not identical and differ slightly from 
each other. In all, chain A has the best density fit and is the most complete chain. The three other 
chains have a lower density fit, especially in the CMGC insert. The chain A has no density in the 
loop AA 409-412, chain B has missing residues AA 213-218 and AA 407-414. Chain C has a gap 
between AA 408-412 and chain D has missing residues AA 408-414 and AA 437-444. One 
feature of the structure described here that distinguishes it from the previous DYRK1A crystal 
structures is the existence of disulfide bridges formed between cysteine C286 of the HCD motive 
in the catalytic loop and cysteine C312 in the activation segment. These disulfide bridges are 




after refinement in chain A, B, C and D are with ~2.06 Å in an ideal distance for disulfide bridges. 
The previously published structure 2VX3
53
 with an open conformation has a cysteine-cysteine 
distance of ~4.3Å. The formation of the disulfide bridge does not have an obvious visible major 
impact on the structure. A superposition of chain A of our structure with chain A from 2VX3 does 
not show any large changes in the structure caused by the disulfide bridge, nor does the disulfide 
bridge interfere with the binding of PKC412. However, it locks the activation segment making the 
loop more rigid (Figure 40) by pulling residue C312 towards the catalytic motif HCD. The 
activation loop is differently folded after the C312, however this part of the DYRK1A kinase is 
flexible and the activation segment adopts different conformations based on the crystal packing. In 
comparison of 4NCT with 2VX3 the loop differs due to a difference in crystal packing (C2 
symmetry). The structures with INDY and harmine 3ANQ and 3ANR have the same crystal 
packing (P212121) and have identical loop conformation like 4NCT. Since the disulfide bridge is 
also missing in these two structures, the local folding around C312 differs too compared to 4NCT. 
The HCD motive is rather rigid and does not move upon the disulfide bridge formation.  
 
           
Figure 40. Structure of DYRK1A in the complex with PKC412 (green) is superimposed with DYRK1A (2VX3, grey). In the 
box is shown a close up picture; the disulfide bridge is formed between C286 and C312 in the DYRK1A in complex with PKC412 
(green), but is absent in the 2VX3 structure (grey). 
 
The formation of the disulfide bridge has however a local effect on the hydrogen network 









hydrogen bond between the backbone carbonyl of I284 and the backbone amid C312 keeps the 
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same length (so the angle changes, Figure 41), however the hydrogen bond between the backbone 
amide I284 to backbone carbonyl C312 gets stretched by ~18% from 2.8 Å to 3.3 Å and in the 
case of the hydrogen bond between the backbone carbonyl H285 and the backbone amide S311 
the distance increase is ~20% from 3.5 Å to 4.2 Å indicating that this hydrogen bond is practically 
non-existent in the structure with the disulfide bridge.   
 
Figure 41.  Superposition of chain A (4NCT, green) with chain A (2VX3, gray) showing the hydrogen bond network 
between the catalytic loop and the activation segment. The formation of the disulfide bridge weakens the hydrogen interactions. 
 
One final feature of the 4NCT structure that further distinguishes it from the previously published 
DYRK1A structures is chain C has a phosphoserine at position S301. This phosphorylation is 
unique to chain C and it is not observed in the other three chains. It is so far not known in the 
literature that S301 can be phosphorylated by DYRK1A and the fact that it is only present in one 
chain indicates that this phosphorylation occurs in only 25% of the protein and might be a rare 
event (Figure 42).  
 
Figure 42. Omit map for serine S301 of chain C (4NCT). The map clearly shows an electron rich group next to the serine that 






4.1 Comparison of DYRK1A and DYRK1B 
 
4.1.1 Expression and purification 
 
DYRK1A and DYRK1B are the closest related kinases in the DYRK family. The sequence 
identity of the kinase domain is 85% and in the ATP pocket there is just one amino acid 
difference: a methionine to leucine exchange. Besides the high similarity, the two proteins behave 
differently when expressed in E. coli. Overexpressed DYRK1B accumulated mostly in inclusion 
bodies and phosphate based buffers have a highly destabilizing effect on DYRK1B, while 
DYRK1A was expressed in high quantities as soluble protein and is less sensitive to different 
buffers.  The overall amount of DYRK1A after purification was on average 20 mg per liter culture 
while DYRK1B had a much lower yield of 2 mg per liter of bacterial culture. It should be 
mentioned that the expression of DYRK1B was high, but the solubility of the protein itself was 
low, causing inclusion body formation, leading to the overall lower amount of purified protein. 
DYRK1B is sensitive to different buffers. Surprisingly it is not the pH that causes the differences, 
but rather the buffering compound and the presence of alkali salts like KCl. The effect of this was 
clearly seen in the thermal shift experiment where the protein had an around 10 degrees lower 
melting temperature in phosphate buffer compared to a HEPES buffer at the same pH. Besides 
these differences, both proteins are expressed as active kinases. The mass spectrometry analysis 
shows that they are phosphorylated on the second tyrosine of the YQY motif in the activation 
segment. This was also true for the DYRK1B L192M and Q164K mutant. The third mutant 
C238R was however not phosphorylated in the activation segment.  
The expression of the mutants followed the protocol for DYRK1B wt. The Q164K mutant 
expressed in a more soluble form and the yield was on average higher compared to the wild type 
DYRK1B. The L192M mutant could be only obtained in a lower yield compared to the wild type 
and Q164K mutant. However it might be possible to optimize the expression of L192M mutant by 
optimizing expression time, temperature and media and using parameters optimal for this mutant. 
Due to the limited time the expression protocol was kept identical for all the mutants.  
Interestingly, DYRK1B L192M elutes as dimer and monomer in the gel filtration in the 
absence of reducing agents. This was also the case for the Q164K mutant in absence of reducing 
agents. DYRK1B has six cysteines in the expression construct. Three of them are buried within 
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the hydrophobic core of the kinase and are not accessible. Besides C238 and C264 that are 
accessible but rather would form an intramolecular disulfide bridge between them, as seen in the 
crystal structure 4NCT, the most likely candidate for an intermolecular disulfide bridge formation 
is C248. It was observed that the lack of reducing agent destabilizes DYRK1B and the mutants 
and they are more likely to precipitate and cannot be concentrated higher than 5 mg/ml. It was 
therefore important to purify DYRK1B in the presence of reducing agents; however, a point 
mutation of C248S might be beneficial for future work. 
The mutant C238R did not express very well and the purification that was done before the 
buffer optimization showed that this kinase is not active. Since the mutant was not phosphorylated 
and the phosphorylation is a posttranslational step during the translation it can be speculated that 
the formation of the disulfide bridge might be essential for this step and proper folding of the 
protein and the lack of activity can be due to a miss-folding in addition to the inactive activation 
segment. Literature data shows that DYRK mutants with phenylalanine instead of tyrosine in the 
activation segment can still be active
18,19
, however with a lower activity. The Cook assay used in 
this thesis might be not sensitive enough to detect very low levels of kinase activity. The C238R 
mutant has, beside its inactivity, interesting properties and offers a way to study the mechanism of 
autoactivation and the necessity of the disulfide bridge for stability and kinase activity. 
 
4.1.2 Enzyme kinetics 
 
The kinetic studies were performed by the Cook assay. One primary observation was that 
DYRK1B phosphorylates DYRKtide faster than DYRK1A. The Km value is with 80 µM 
compared to 118µM in DYRK1A lower which means that DYRK1B has a higher affinity to ATP. 
The Km value for DYRK1B correlates strongly with the Kd value for ATP obtained by microscale 
thermophoresis (NanoTemper). Our observation with the kinase activity assay indicates that 
DYRK1B is more active than DYRK1A which is shown in the Km values, however since our 
assays were performed at room temperature the kinases were most probably not operating at a 
their temperature optima. The Km values measured in this thesis for DYRK1A differ from the Km 
value reported in the literature which was 35 µM
29
; i.e., four times lower. A direct comparison 
might be so not valid since the Km values were determined with different assays and at different 
temperatures. The higher temperature of 30 degree used in the radiometric assay by Himpel et al.
29
 
might be closer to a temperature optimum. This higher activity of the kinases at higher 





The only difference in the ATP pocket between DYRK1A and DYRK1B is the more bulky 
but unbranched methionine in DYRK1A compared to the smaller leucine in DYRK1B in the hinge 
region. (P+2 from gatekeeper residue)  The methionine in the crystal structure points away from 
the binding pocket and it does not give the impression that methionine could block the ATP 
pocket. It is however possible that since the amino acid is flexible it causes some steric hindrance 
in the path for ATP to the pocket which could explain the lower activity of DYRK1A compared 
with DYRK1B.  However, a mutant of DYRK1B where the leucine in the hinge is replaced by a 
methionine has a reduced activity even lower than DYRK1A. The Km value for the L192M mutant 
was 1400 nM, ten times weaker than DYRK1A. There is no obvious explanation for this 
unexpected weaker Km value. If correct, an additional mechanism that influences the kinase 
activity must exist. Since there are not many other residues close by that are different between 
DYRK1A and DYRK1B that could be responsible for this effect it could be a simple problem of 
stability of the L192M mutant in the assay conditions. However, neither DYRK1A nor DYRK1B 
wt have stability problems in the activity assay. One other possibility is a tryptophan (W184) at 
the beginning at β-sheet 3 in DYRK1A that could hold the methionine residue away from the ATP 
pocket via hydrophobic interactions. In DYRK1B this residue is a leucine, a small hydrophobic 
residue that might not be able to do so. It needs however more investigation whether this is a 
possible mechanism. The distance (in the structure of DYRK1A (4NTC)) between W184 and 
L240 is, with around 5-8 Å, large for hydrophobic interactions. A double mutant of DYRK1B 
with L192M and L137W might be needed to investigate the potential role of the tryptophan. The 
IC50 value of PKC412 for DYRK1B L192M is 2.5 times weaker compared to the wild type kinases 
DYRK1A and DYRK1B which also would indicate that additional factors are involved in the 
selectivity for ATP and inhibitor interaction with these kinases. 
 
4.1.3 Comparison in inhibitor screen 
 
The inhibitors, provided by a private pharmaceutical company, were originally designed for 
the inhibition of DYRK1A. However the close relation between DYRK1A and DYRK1B makes it 
obvious to test these inhibitors also for DYRK1B and derive a selectivity profile. The 
experimental results demonstrate that the potency of inhibitors is, in general, higher for DYRK1A 
than for DYRK1B; however exceptions exist. The graphical representation of the Table 7 and 
Figure 48 (appendix) shows that there are three inhibitors (15, 26 and 48) that are significant 
better for DYRK1B compared to DYRK1A. An additional ten inhibitors (23, 25, 27, 37, 39, 40, 
41, 44, 47 and 49) have a preference for DYRK1B, however the difference is less significant. On 
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the other hand, 21 inhibitors are significantly more selective for DYRK1A and the remaining 16 
inhibitors have a minor preference for DYRK1A or do not distinguish between the two kinases.  
The screening assay for the 50 inhibitors was performed at a fixed concentration of inhibitor 
(20 µM). For a more detailed analysis of inhibitor potency, the determination of IC50 followed by 
Ki calculation was performed for some inhibitors using the Cook assay and a serial dilution of 
inhibitor concentrations. In the case of harmine, the IC50 determination for DYRK1B wt and the 
L192M mutant show similar IC50 values, however if the L192M mutant has lower affinity for ATP 
(Km is 1,4 mM) compared to DYRK1B wt (Km is 80 µM), then for L192M a lower concentration 
of inhibitor is required to reduce the kinase activity to 50%. The calculation of Ki for harmine 
shows that harmine binds stronger to DYRK1B wt by a factor of two (Ki is 337 nM) compared to 
the L192M mutant (Ki is 601 nM). We would expect that harmine binds stronger to the L192M 
mutant since it mimics DYRK1A and in the scientific literature a stronger affinity of harmine 
towards DYRK1A over DYRK1B was shown
133
. Nevertheless the ~10 fold lower Km of L192M 
compared to DYRK1A and almost ~20 times lower Km towards DYRK1B would result in a 
decrease in Ki value for this mutant. The fact that the order for the binding strength is reversed 
when comparing IC50 values to Ki values makes it important in competitive inhibitor assays to not 
only determine the binding strength of the inhibitor but also to take into consideration the binding 
strength of the substrate that has to be replaced. The IC50 determination gives the inhibitor 
concentration at which 50% of the protein is inactive, but to compare actual binding strength of 
inhibitors the Ki values might be more suitable and independent of the ATP substrate 
concentration. The difference in IC50 values and Ki values are most prominent in cases where the 
Km values for ATP are significantly different. The closer similarity of the Km values between 
DYRK1A and DYRK1B wt do not influence the Ki determination that much and the IC50 values 
are more comparable with the Ki values meaning that the affinity arose from the IC50 is direct 
proportional to the affinities determined by the Ki values. This is seen in the PKC412 titration for 
DYRK1A and DYRK1B which have similar affinities by comparing IC50 values or Ki values.    
In addition to harmine, four inhibitors synthesized and provided by the company were 
selected for IC50 determination and Ki calculation for DYRK1B. A more precise determination of 
inhibitor potency by Ki calculation revealed that the most potent inhibitor, among the inhibitors 
synthesized and provided by the private company, was inhibitor 4 (Ki is 625 nM) which was in the 
third place in the rank of inhibitors, based on the initial screen at a fixed inhibitor concentration, 
after inhibitor 47 and harmine. Inhibitor 47, based on the result of the inhibitor screen, was the 
best one, but in the ranking according to the Ki values it binds weaker (685 nM) than harmine 




only 9%. This shows, in conclusion, that the testing of inhibitors with one particular inhibitor 
concentration is efficient for fast screening for the strongest inhibitors, but ranking inhibitors 
solely based on one inhibitor concentration can only be a preliminary step. For full verification a 
more precise analysis of inhibitor binding or determination of Ki value is required. Nevertheless is 
an inhibitor screen based on one inhibitor concentration is practical and useful to rapidly eliminate 
inhibitors that do not, or only marginally, inhibit the target enzyme. In this way the more time 




4.2.1 Structure of DYRK1A 
 
It was unfortunately not possible to crystalize DYRK1B, however due to the close similarity 
between DYRK1A and DYRK1B, the structure of DYRK1A in complex with PKC412 
crystallized and solved in this thesis offers a good model for DYRK1B. The kinetic data for 
PKC412 show that both kinases are inhibited equally well by PKC412 and it can be assumed that 
the binding of PKC412 is identical in both kinases. DYRK1A crystallized with disulfide bridges 
formed which is a novel finding since the previously published DYRK1A structures do not have 
disulfide bridges. It was speculated so that the formation of disulfide bridges is involved in 
tweaking the activity of the kinase. The structure with the disulfide bridge does not show any 
major structural rearrangements. As discussed in the results section, it weakens the hydrogen bond 
network between the activation segment and the catalytic loop and replaces it with a stronger 
covalent S-S-bond. Our observation from the expression of the C238R mutant which is not 
phosphorylated at tyrosine Y273 might suggest that the disulfide bridge formation is essential 
during the autophosphorylation in the translation step. It needs however more research to settle 
this problem. Another finding in the DYRK1A structure was a phosphoserine S301. This 
phosphorylation site was previously not described in the literature. It is only present on chain C in 
the asymmetric unit. One of the tested crystals of DYRK1A/PKC412 solved by us diffracted to 3Å 
and, had a high twinning fraction of 0.6 to 0.4 (H, K, L/ K, H, -L) while there was no twinning in 
the 4NCT structure. The two crystals came from different protein batches, and it might be possible 
that the phosphorylation on S301 in 25% of the protein helped to orientate the asymmetric unit in 




4.2.2 Disulfide bridge 
 
The HCD motif in the catalytic loop in DYRK kinases is rare in the human kinome (Figure 
43). Besides the DYRK family it is only found in a few other kinases like the PKD family (protein 
kinase D faimily), the Tyrosine-protein kinase SgK269 (sugen kinase 269), ULK4 (uridine kinase-
like protein 4) and LRRK1 (Leucine-rich repeat serine/threonine-protein kinase 1) that have a 
cysteine at this position. (ULK4 and LRRK1 have a FCD motif). Among these, only UKL4 has a 
second cysteine in the activation segment between the DFG and APE motifs that could act like a 
partner for disulfide bridge formation as in DYRK1A. The PKD kinases have no cysteine in the 
activation segment between the residues DFG and APE however they have a cysteine right in 
front of the DFG, and the CDFG motif is conserved among the three PKD kinases. Whether these 
kinases are able to form disulfide bridges to the cysteine in the extended activation segment or to 
other cysteines in the kinase domain can only be speculated upon due to the lack of structural 
information.  Preliminary observations of the DYRK1B mutant with the HCD motif mutated to 
HRD (C238R) show that the E. coli expressed protein was not enzymatically active in the kinase 
assay. However as discussed above the Cook assay might not be sensitive enough to detect low 
activity, and a radiometric assay might be more accurate in this respect. It needs further studies to 
investigate whether the HCD and the disulfide bridge are mandatory for tyrosine phosphorylation 
and autoactivation, or whether the disulfide bridge plays a role in the kinase activity. 
 
Figure 43. Distribution of the second residue of the HRD catalytic motif in human kinome. Cysteine residue is in yellow. 






The DYRK1A structure 4NCT is the first kinase in the protein data bank which has a PKC412 
molecule bound to the ATP pocket. There exists however several kinase structures with 
staurosporine the original isolated natural compound from which PKC412 was derived. Like 
staurosporine PKC412 inhibits many kinases in the kinome, however its inhibitory profile is more 
selective. The structure of DYRK1A with PKC412 might help to understand this profile and can 
serve as a starting point to develop more selective inhibitors for DYRK kinases. Some 
modification that might lead to a stronger binder would be to introduce a hydrogen acceptor 
opposite of the hinge to bind to K188 as it is seen in the inhibitors INDY and harmine
16
. Another 
modification could be an extension of the “tail” to anchor the inhibitor via hydrogen bonds to 
E291 or N244 (Figure 44). Additional extensions to introduce hydrogen bonds to D305 from the 
DFG motive are possible.  
  
 
Figure 44. The PKC412 (purple) bound to the ATP-pocket of DYRK1A (4NCT). The green residues are involved in hydrogen 
bond formation, the black residues are amino acids in close proximity that could serve as hydrogen bond partners. 
 
 PKC412 is widely used in clinical trials to treat acute myeloid leukemia and other cancers 
and it is currently in clinical trials as an inhibitor for FLT3
71
. A possible application in 
neurological disease is not established. Since DYRK1A is a kinase involved in neurological 
disease it may be possible to expand the clinical trials to neurological diseases. 
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5. FUTURE WORK 
 
Many questions could be answered by obtaining a crystal structure of DYRK1B. For this 
purpose it would be necessary to try new constructs with different lengths compared to the 
construct used in this master project. The different constructs could contain the point mutations at 
the position of the possible crystal contact like Q164K used, but also include new point mutations 
like C248S, a residue most probably involved in dimerization in the absence of reducing agent. 
For each mutant and construct it would be necessary to optimize the buffers in order to obtain the 
most stable protein. Another option would be to focus on the inclusion bodies. DYRK1B is highly 
expressed but most of the protein stays in the insoluble fraction after lysis. Finding a protocol for 
refolding would overcome the shortage of protein and would allow for more numerous and 
extensive crystallization screens.   
For the kinetics it would be interesting to further study the inhibitor selectivity profile. It is 
necessary to make DYRK1A mutants that mimic DYRK1B like a DYRK1A M240L where the 
hinge methionine in DYRK1A is replaced by a leucine found in DYRK1B at this position. It 
would be the reverse mutation to the DYRK1B L192M used in this thesis. Also, the potential role 
of W184 (L137 in DYRK1B) could be investigated by a point mutation. 
Finally, the HCD could be investigated in more detail. Point mutation of the HCD motif to 
HSD or mutagenesis of the cysteine binding partner C264 (C312 in DYRK1A) could be 
performed.     
In addition to the Cook assay, a second binding assay should be established. Since most of the 
company‟s provided inhibitors are poorly water soluble and the Biacore did not work due to 
instability of the protein on the chip, the microthermophoresis technology could be an alternative 
and a supplement to the kinetic assay.  
And finally, it can be proposed to continue the research on PKC412 as a drug candidate for 












The research within this thesis describes the biophysical characterization of DYRK1B, a 
member of the dual-specificity tyrosine phosphorylation-regulated kinase family (DYRKs) which 
have recently emerged as new therapeutic targets for various kinds of cancer and 
neurodegenerative diseases.  DYRK1B plays a key role for cancer cell survival, and its inhibition 
induces apoptosis of cancer cells. This thesis describes the cloning of the kinase domain of 
DYRK1B. The construct contains a (His)6-tag, TEV protease cleavage site and the kinase domain 
(AA 78-451).  DYRK1B was expressed and purified by affinity chromatography (HisTrap Ni-
NTA columns) followed by a TEV cleavage - to remove the Histag - during dialysis and a second 
HisTrap purification. For the crystallization trails a size exclusion chromatography (SEC) was 
used as last step resulting in production of to 98% pure protein. 
 To study the stability and solubility of DYRK1B two buffer screens were designed. The 
buffer screens, carried out by Thermofluor, showed that HEPES buffer increased the melting 
temperature by 12   compared to initially used phosphate buffer. The buffer optimization 
improved the yield of DYRK1B by 10 fold.  In the absence of reducing agent, DYRK1B 
dimerizes and these dimers could be separated from the monomers via SEC.  Three mutants of 
DYRK1B were cloned in this master project to investigate different aspects of enzymatic activity 
(C238R), selectivity (L192M) and crystallisability (Q164K).  DYRK1B C238R was not 
autophosphorylated at Y273 and did not show activity in the cook assay; however this mutant 
needs to be further investigated with a more sensitive assay. DYRK1B L192M and DYRK1B 
Q164K were expressed as active enzymes and were used for their designed purposes: inhibitor 
selectivity profiling and crystallization trials, respectively.  
50 inhibitors were screened to determine the selectivity of DYRK1B versus DYRK1A. The 
best inhibitors were chosen for IC50 determination and Ki calculation. The point mutation 
DYRK1B L192M that mimics DYRK1A in the ATP pocket was used to study the influence of 
methionine in the hinge region on the selectivity profile of the inhibitors. The Michaelis-Menten 
constant Km was determined by Cook assay for DYRK1A, DYRK1B wt and DYRK1B L192M. 
DYRK1B has the highest affinity for ATP with a Km of 81 µM, DYRK1A has a weaker affinity of 
Km = 119 µM. In contrast to the two wild type kinases, the Km value for DYRK1B L192M drops 
by almost 20 times to 1400 µM. This significantly weaker Km, if correct, leads to the conclusion 
that DYRK1A probably has additional residues close to the ATP pocket that could compensate for 
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a weaker ATP affinity. As a possible candidate, a tryptophan W184, was identified that is close to 
M240 and probably interacts with methionine. In DYRK1B this residue is L137.    
Crystallization trials with DYRK1B wt, DYRK1B Q164K and DYRK1A were performed 
with commercially available inhibitors. Unfortunately, DYRK1B did not crystallize but DYRK1A 
was crystallized in complex with inhibitor PKC412. The diffraction data were collected at BESSY 
II beamline 14.1 (Helmholz Zentrum Berlin). The crystal diffracted at resolution 2.6 Å. The 
structure was solved by molecular replacement in Molrep (CCP4) and refined by Refmac5 and 
Phenix. The crystal structure demonstrates a formation of the disulfide bridge between C286 in the 
catalytic motif HCD and C312 in the activation segment. This crystal structure is the first 
DYRK1A structure with a disulfide bridge and it is the first kinase with the staurosporine analog 
























































































































Table 13. Stability and Solubility Screen 1. 
well Buffer Salt Additive 
# name mM pH name mM name mM 
A01 TricCl 100 7 
    A02 
  
7 NaCl 800 
  A03 
  
7 KCl 800 
  A04 
  
7 LiCl 800 
  A05 TricCl 100 8 
    A06 
   
NaCl 800 
  A07 
   
KCl 800 
  A08 
   
LiCl 800 
  A09 MOPS 100 6,5 
    A10 
   
NaCl 800 
  A11 
   
KCl 800 
  A12 
   
LiCl 800 
  B01 MOPS 100 7 
    B02 
   
NaCl 800 
  B03 
   
KCl 800 
  B04 
   
LiCl 800 
  B05 MOPS 100 7,5 
    B06 
   
NaCl 800 
  B07 
   
KCl 800 
  B08 
   
LiCl 800 
  B09 MOPS 100 8 
    B10 
   
NaCl 800 
  B11 
   
KCl 800 
  B12 
   
LiCl 800 
  C01 Tris 100 7,5 
    C02 
   
NaCl 800 
  C03 
   
KCl 800 
  C04 
   
LiCl 800 
  C05 Tris 100 8,5 
    C06 
   
NaCl 800 
  C07 
   
KCl 800 
  C08 
   
LiCl 800 
  C09 HEPES 100 6,5 
    C10 
   
NaCl 800 
  C11 
   
KCl 800 
  C12 
   
LiCl 800 
  D01 HEPES 100 7 
    D02 
   
NaCl 800 
  D03 
   
KCl 800 
  D04 
   
LiCl 800 
  D05 HEPES 100 7,5 
    D06 
   
NaCl 800 
  D07 
   
KCl 800 
  D08 
   
LiCl 800 
  D09 HEPES 100 8 
    D10 
   
NaCl 800 
  D11 
   
KCl 800 
  D12 
   
LiCl 800 
  E01 MES 100 5,5 
    E02 
   
NaCl 800 
  E03 
   
KCl 800 
  E04 
   
LiCl 800 
  E05 MES 100 6 
    E06 
   
NaCl 800 
  E07 
   
KCl 800 
  E08 
   
LiCl 800 
  E09 MES 100 6,5 
    E10 
   
NaCl 800 
  E11 
   
KCl 800 
  E12 
   
LiCl 800 
  F01 Bistris 100 5,5 
    F02 
   
NaCl 800 
  F03 
   
KCl 800 
  F04 





F05 Bistris 100 6 
    F06 
   
NaCl 800 
  F07 
   
KCl 800 
  F08 
   
LiCl 800 
  F09 Bistris 100 6,5 
    F10 
   
NaCl 800 
  F11 
   
KCl 800 
  F12 
   
LiCl 800 
  G01 Bistris 100 7 
    G02 
   
NaCl 800 
  G03 
   
KCl 800 
  G04 
   
LiCl 800 
  G05 TricCl 100 7 NaCl 800 Chaps 20 
G06 TricCl 100 8 NaCl 800 Chaps 20 
G07 MOPS 100 6,5 NaCl 800 Chaps 20 
G08 MOPS 100 7 NaCl 800 Chaps 20 
G09 MOPS 100 7,5 NaCl 800 Chaps 20 
G10 MOPS 100 8 NaCl 800 Chaps 20 
G11 Tris 100 7,5 NaCl 800 Chaps 20 
G12 Tris 100 8,5 NaCl 800 Chaps 20 
H01 HEPES 100 6,5 NaCl 800 Chaps 20 
H02 HEPES 100 7 NaCl 800 Chaps 20 
H03 HEPES 100 7,5 NaCl 800 Chaps 20 
H04 HEPES 100 8 NaCl 800 Chaps 20 
H05 MES 100 5,5 NaCl 800 Chaps 20 
H06 MES 100 6 NaCl 800 Chaps 20 
H07 MES 100 6,5 NaCl 800 Chaps 20 
H08 Bistris 100 5,5 NaCl 800 Chaps 20 
H09 Bistris 100 6 NaCl 800 Chaps 20 
H10 Bistris 100 6,5 NaCl 800 Chaps 20 
H11 Bistris 100 7 NaCl 800 Chaps 20 
H12 H2O 


















Table 14. Stability and Solubility Screen 2 
well Buffer Salt 
# name mM pH name mM 
A01 TricCl 100 7 +KCl 100 
A02 
   
+KCl 200 
A03 
   
+KCl 300 
A04 
   
+KCl 400 
A05 TricCl 100 8 +KCl 100 
A06 
   
+KCl 200 
A07 
   
+KCl 300 
A08 
   
+KCl 400 
A09 MOPS 100 6,5 +KCl 100 
A10 
   
+KCl 200 
A11 
   
+KCl 300 
A12 
   
+KCl 400 
B01 MOPS 100 7 +KCl 100 
B02 
   
+KCl 200 
B03 
   
+KCl 300 
B04 
   
+KCl 400 
B05 HEPES 100 6,5 +KCl 100 
B06 
   
+KCl 200 
B07 
   
+KCl 300 
B08 
   
+KCl 400 
B09 HEPES 100 7 +KCl 100 
B10 
   
+KCl 200 
B11 
   
+KCl 300 
B12 
   
+KCl 400 
C01 HEPES 100 7,5 +KCl 100 
C02 
   
+KCl 200 
C03 
   
+KCl 300 
C04 
   
+KCl 400 
C05 HEPES 100 8 +KCl 100 
C06 
   
+KCl 200 
C07 
   
+KCl 300 
C08 
   
+KCl 400 
C09 MES 100 5,5 +KCl 100 
C10 
   
+KCl 200 
C11 
   
+KCl 300 
C12 
   
+KCl 400 
D01 MES 100 6 +KCl 100 
D02 
   
+KCl 200 
D03 
   
+KCl 300 
D04 
   
+KCl 400 
D05 MES 100 6,5 +KCl 100 
D06 
   
+KCl 200 
D07 
   
+KCl 300 
D08 
   
+KCl 400 
D09 Bistris 100 5,5 +KCl 100 
D10 
   
+KCl 200 
D11 
   
+KCl 300 
D12 
   
+KCl 400 
E01 Bistris 100 6 +KCl 100 
E02 
   
+KCl 200 
E03 
   
+KCl 300 
E04 
   
+KCl 400 
E05 Bistris 100 6,5 +KCl 100 
E06 
   
+KCl 200 
E07 
   
+KCl 300 
E08 
   
+KCl 400 
E09 PBS 100 7 +KCl 100 
E10 
   
+KCl 200 
E11 
   
+KCl 300 
E12 
   
+KCl 400 
F01 













Figure 48. The comparison of remaining activity (%) of 50 inhibitors between DYRK1A 
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